Engineered and chimeric nucleases
By using Class 2 Type II Cas endonuclease and engineered guide RNA to match targeted sequences of specific loci, the problem of insufficient matching and selectivity of targeted sequences in gene editing of the CRISPR/Cas system is solved, and the problem of insufficient matching and selectivity of targeted sequences in gene editing is achieved. The efficient destruction of loci such as VCP and TRAC has improved editing efficiency and accuracy.
Patent Information
- Application Number
- CN202380027953.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-01-30
- Filing Date
- 2023-03-14
- Publication Date
- 2024-12-06
AI Technical Summary
The existing CRISPR/Cas system has problems with insufficient targeted sequence matching and endonuclease selectivity in gene editing and DNA manipulation, resulting in limited gene editing efficiency and accuracy.
Using 2 types of Cas endonucleases and engineered guide RNA, the complexes are configured to match targeting sequences of specific loci, so as to achieve the loci such as VCP, TRAC, AAVS1, PCSK9, ANGPTL3, GPR146, APOA1, etc. efficient destruction.
It improves the efficiency and accuracy of gene editing, ensures high matching and selectivity of targeted sequences, and enhances the ability to destroy specific loci.
Smart Images

Figure CN119095954A_ABST
Abstract
Description
[0001] Cross-reference to related applications
[0002] This application claims the benefit of and priority to U.S. Provisional Patent Application No. 63 / 319,725 filed on March 14, 2022, U.S. Provisional Patent Application No. 63 / 335,542 filed on April 27, 2022, U.S. Provisional Patent Application No. 63 / 392,814 filed on July 27, 2022, and U.S. Provisional Patent Application No. 63 / 482,294 filed on January 30, 2023, each of which is incorporated herein by reference in its entirety. Technical Field
[0003] Cas enzymes and their associated clustered regularly interspaced short palindromic repeats (CRISPR) guide RNAs appear to be universal (~45% of bacteria, ~84% of archaea) components of the prokaryotic immune system, used to protect such microorganisms from non-self nucleic acids, such as infectious viruses and plasmids, through CRISPR-RNA-guided nucleic acid cleavage. While the deoxyribonucleic acid (DNA) elements encoding CRISPR RNA elements may be relatively conserved in structure and length, their CRISPR-associated (Cas) proteins are highly diverse, containing a variety of nucleic acid interaction domains. Although CRISPR DNA elements were observed as early as 1987, the programmable endonuclease cleavage capacity of the CRISPR / Cas complex was only recently recognized, leading to the use of recombinant CRISPR / Cas systems in various DNA manipulation and gene editing applications.
[0004] Sequence Listing
[0005] This application contains a sequence listing that has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. The XML copy, created on March 14, 2023, is named MTG-010WO_SL.xml and is 4,575,581 bytes in size. Summary of the Invention
[0006] In some aspects, the present disclosure provides a method for destroying a VCP locus in a cell, the method comprising introducing into the cell: (a) 2 class II type Cas endonucleases; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a targeting sequence configured to hybridize to a region of the VCP locus, wherein the engineered guide RNA is configured to hybridize to or comprise a targeting sequence having at least 80% identity to SEQ ID NOs: 739-754 or 763-770; or wherein the engineered guide RNA comprises a sequence having at least 80% identity to any one of SEQ ID NOs: 723-738 or 755-762. In some embodiments, the 2 class II type Cas endonucleases comprise any one of the engineered endonucleases described herein. In some embodiments, the 2 class II type Cas endonucleases comprise a fusion endonuclease having at least 55% identity to SEQ ID NO: 10 or a variant thereof. In some embodiments, the engineered guide RNA comprises a sequence that is at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the non-degenerate nucleotides of SEQ ID NO: 722 or SEQ ID NO: 863. In some embodiments, the engineered guide RNA is complementary to or comprises a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOs: 743-745, 749-752, 754, or 769. In some embodiments, the engineered guide RNA comprises the nucleotide sequence of any one of the guide RNAs of Table 22B comprising the chemical modifications described in Table 22B.
[0007] In some cases, the present disclosure provides a fusion endonuclease comprising: (a) an N-terminal sequence comprising at least a portion of a RuvC-I domain, a REC domain, a RuvC-II domain, a HNH domain, or a RuvC-III domain of an endonuclease having at least 55%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 696 or a variant thereof; and (b) a C-terminal Sequences, the C-terminal sequences include MG3-1, MG3-2, MG3-3, MG3-4, MG3-5, MG3-6, MG3-7, MG3-8, MG3-18, MG3-22, MG3-24, MG3-30, MG3-42, MG3-78, MG3-89, MG3-90, MG3-91, MG3-92, MG3-93, MG3-94, MG3-95, MG3-96, MG3-101, MG3-103, MG3-104, MG150-1, MG150-2, MG150-3, MG150-4, 0-4, MG150-5, MG150-6, MG150-7, MG150-8, MG150-9, MG150-10, MG15-1, MG15-54, MG15-66, MG15-94, MG15-115, MG15-135, MG1 5-146, MG15-164, MG15-166, MG15-171, MG15-172, MG15-174, MG15-177, MG15-184, MG15-187, MG15-191, MG15-193, MG15-195, M G15-217, MG15-218 or MG15-219 or variants thereof have a WED or PI domain of an endonuclease having at least 55%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity, wherein the N-terminal sequence and the C-terminal sequence do not naturally occur together in the same reading frame. In some embodiments, the N-terminal sequence and the C-terminal sequence are derived from different organisms.In some embodiments, the fusion endonuclease comprises a sequence having at least 55%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOs: 771-862 or a variant thereof. In some embodiments, the fusion endonuclease is configured to be selective for a PAM that is not nnRGGnT. In some embodiments, the fusion endonuclease is configured to be selective for a PAM comprising any one of SEQ ID NOs: 865-919. In some embodiments, the fusion endonuclease comprises a WED domain and a PI domain, wherein the WED domain is from an endonuclease having at least 55% sequence identity to MG3-8, and the PI domain is from an endonuclease having at least 55% sequence identity to MG3-1, MG3-2, MG3-3, MG3-4, MG3-5, MG3-6, MG3-7, MG3-8, MG3-18, MG3-22, MG3-24, MG3-30, MG3-42, MG3-78, MG3-89, MG3-90, MG3-91, MG3-92, MG3-93, MG3-94, MG3-95, MG3-96, MG3-101, MG3-103, MG3-104, MG150-1, MG150-2, MG150-3 , MG150-4, MG150-5, MG150-6, MG150-7, MG150-8, MG150-9, MG150-10, MG15-1, MG15-54, MG15-66, MG15-94, MG15-115, MG15-135, MG15-146, MG15-164, MG15-166, MG15-171, MG15-172, MG15-174, MG15-177, MG15-184, MG15-187, MG15-191, MG15-193, MG15-195, MG15-217, MG15-218, or MG15-219, or a variant thereof.
[0008] In some aspects, the present disclosure provides a nuclease comprising an engineered amino acid sequence having at least 55%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to any one of SEQ ID NOs: 771-862 or a variant thereof. In some embodiments, the endonuclease comprises an engineered amino acid sequence having at least 55%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any of SEQ ID NOs: 809-823, 827, 829-830, 832, 834, or 838-839.
[0009] In some aspects, the present disclosure provides an engineered nuclease system comprising: (a) any of the endonucleases described herein; and (b) an engineered guide RNA structure configured to form a complex with the endonuclease, the engineered guide RNA structure comprising: a guide RNA configured to hybridize with a target deoxyribonucleic acid sequence; wherein the guide RNA sequence is configured to bind to the endonuclease. In some embodiments, the guide RNA further comprises a tracr RNA sequence configured to bind to the endonuclease. In some embodiments, the endonuclease is derived from an uncultured microorganism. In some embodiments, the endonuclease is not Cas9 endonuclease, Cas14 endonuclease, Cas12a endonuclease, Cas12b endonuclease, Cas 12c endonuclease, Cas12d endonuclease, Cas12e endonuclease, Cas13a endonuclease, Cas13b endonuclease, Cas13c endonuclease or Cas13d endonuclease. In some embodiments, the endonuclease has less than 86% identity to SpyCas9 endonuclease. In some embodiments, the endonuclease comprises a sequence having at least 55%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOs: 771-862, or a variant thereof. In some embodiments, the guide ribonucleic acid sequence comprises a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the non-degenerate nucleotides of SEQ ID NO: 722 or SEQ ID NO: 863.
[0010] In some aspects, the present disclosure provides a method of disrupting a TRAC locus in a cell, the method comprising introducing into the cell: (a) 2 class II type Cas endonucleases; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease, and the engineered guide RNA comprises a targeting sequence configured to hybridize to a region of the TRAC locus, wherein the engineered guide RNA is configured to hybridize to SEQ ID NO: NO:925-927, 992-1011, 1184-1279 or 1321-1361 having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity hybridizes with or includes the targeting sequence; or wherein the engineered guide RNA includes the target sequence of SEQ ID Any of NOs: 922-924, 972-991, 1088-1183, or 1280-1320 has a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity. In some embodiments, the 2 Class II type Cas endonucleases comprise a fusion endonuclease described herein or comprise a sequence having at least at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 771. In some embodiments, the engineered guide RNA comprises a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the non-degenerate nucleotides of SEQ ID NO: 722 or SEQ ID NO: 863.
[0011] In some aspects, the present disclosure provides a method of disrupting an AAVS1 locus in a cell, the method comprising introducing into the cell: (a) 2 class II type Cas endonucleases; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a targeting sequence configured to hybridize to a region of the AAVS1 locus, wherein the engineered guide RNA is configured to hybridize to or comprise a targeting sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NOs: 950-971 or 1050-1087; or wherein the engineered guide RNA comprises a targeting sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NOs: 950-971 or 1050-1087; Any of NOs: 928-949 or 1012-1049 has a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity. In some embodiments, the 2 Class II type Cas endonucleases comprise a fusion endonuclease described herein or comprise a sequence having at least at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 771. In some embodiments, the engineered guide RNA comprises a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the non-degenerate nucleotides of SEQ ID NO: 722 or SEQ ID NO: 863.
[0012] In some aspects, the disclosure provides a method of disrupting a PCSK9 locus in a cell, the method comprising introducing into the cell: (a) 2 Class II type Cas endonucleases; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a targeting sequence configured to hybridize to a region of the PCSK9 locus, wherein the engineered guide RNA is configured to hybridize to or comprise a targeting sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NOs: 1377-1391; or wherein the engineered guide RNA comprises a targeting sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NOs: 1377-1391; NO:1362-1376 has a sequence with at least 80% identity. In some embodiments, the 2 Class II Type Cas endonucleases include fusion endonucleases described herein. In some embodiments, the 2 Class II Type Cas endonucleases include fusion endonucleases having at least 55%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO:10 or a variant thereof. In some embodiments, the engineered guide RNA comprises a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the non-degenerate nucleotides of SEQ ID NO: 722 or SEQ ID NO: 863.
[0013] In some aspects, the present disclosure provides a method of disrupting an ANGPTL3 locus in a cell, the method comprising introducing into the cell: (a) a Class 2 type II Cas endonuclease; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a targeting sequence configured to hybridize to a region of the ANGPTL3 locus, wherein the engineered guide RNA is configured to hybridize to or comprise a targeting sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NOs: 1490-1587; or wherein the engineered guide RNA comprises a targeting sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NOs: 1490-1587. Any one of NOs: 1392-1489 has a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity. In some embodiments, the 2 Class II type Cas endonucleases include fusion endonucleases described herein. In some embodiments, the 2 Class II type Cas endonucleases comprise fusion endonucleases having at least 55%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 10 or a variant thereof. In some embodiments, the engineered guide RNA comprises a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the non-degenerate nucleotides of SEQ ID NO: 722 or SEQ ID NO: 863.
[0014] In some aspects, the present disclosure provides a method of disrupting a GPR146 locus in a cell, the method comprising introducing into the cell: (a) 2 Class II type Cas endonucleases; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a targeting sequence configured to hybridize to a region of the GPR146 locus, wherein the engineered guide RNA is configured to hybridize to or comprise a targeting sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NOs: 1657-1725; or wherein the engineered guide RNA comprises a targeting sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NOs: 1657-1725. Any one of NO:1588-1656 has a sequence with at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity. In some embodiments, the 2 Class II type Cas endonucleases include fusion endonucleases described herein. In some embodiments, the engineered guide RNA comprises a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the non-degenerate nucleotides of SEQ ID NO: 722 or SEQ ID NO: 863.
[0015] In some aspects, the present disclosure provides a method of disrupting an APOA1 locus in a cell, the method comprising introducing into the cell: (a) a Class II type Cas endonuclease; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a targeting sequence configured to hybridize to a region of the APOA1 locus, wherein the engineered guide RNA is configured to hybridize to or comprise a targeting sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NOs: 1745-1763 or 1775-1785; or wherein the engineered guide RNA comprises a targeting sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NOs: 1745-1763 or 1775-1785; Any one of NO:1726-1744 or 1764-1774 has a sequence with at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity. In some embodiments, the 2 Class II type Cas endonucleases include fusion endonucleases described herein. In some embodiments, the engineered guide RNA comprises a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the non-degenerate nucleotides of SEQ ID NO: 722 or SEQ ID NO: 863.
[0016] In some aspects, the present disclosure provides a lipid nanoparticle comprising: (a) any of the endonucleases described herein; (b) any of the engineered guide RNAs described herein; (c) a cationic lipid; (d) a sterol; (e) a neutral lipid; and (f) a PEG-modified lipid. In some embodiments, the cationic lipid comprises C12-200, the sterol comprises cholesterol, the neutral lipid comprises DOPE, or the PEG-modified lipid comprises DMG-PEG2000. In some embodiments, the cationic lipid comprises Figure 45Any of the cationic lipids depicted.
[0017] In some aspects, the present disclosure provides a fusion endonuclease comprising: (a) an N-terminal sequence comprising at least a portion of a RuvC domain, a REC domain, or a HNH domain of an endonuclease having at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 696 or a variant thereof; and (b) a C-terminal sequence comprising at least a portion of a RuvC domain, a REC domain, or a HNH domain of an endonuclease having at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 696 or a variant thereof; Any one of NO:697-721 or its variant has at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity of the endonuclease WED, TOPO or CTD domain, wherein the N-terminal sequence and the C-terminal sequence do not naturally appear together in the same reading frame. In some embodiments, the endonuclease is a 2 type II Cas endonuclease. In some embodiments, the endonuclease is a 2 type V Cas endonuclease. In some embodiments, the N-terminal sequence and the C-terminal sequence are derived from different organisms. In some embodiments, the N-terminal sequence further comprises RuvC-I, BH, and RuvC-II domains. In some embodiments, the C-terminal sequence further comprises a PAM interaction domain. In some embodiments, the fusion endonuclease comprises a sequence having at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOs: 1-27 or 108. In some embodiments, the fusion endonuclease is configured to bind to a PAM that is not nnRGGnT.
[0018] In some aspects, the present disclosure provides a nuclease comprising an engineered amino acid sequence having at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to any one of SEQ ID NOs: 1-27 or 108, or a variant thereof.
[0019] In some aspects, the present disclosure provides a nuclease comprising an engineered amino acid sequence having at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOs: 109-110, or a variant thereof.
[0020] In some aspects, the present disclosure provides a nucleic acid comprising a sequence encoding any of the endonucleases, fusion endonucleases, or Cas enzymes described herein. In some aspects, the sequence is codon-optimized for expression in a host cell. In some embodiments, the host cell is a prokaryotic, eukaryotic, mammalian, or human host cell.
[0021] In some aspects, the present disclosure provides a vector comprising any of the nucleic acid sequences described herein.
[0022] In some aspects, the present disclosure provides a host cell comprising any of the vectors, systems, or nucleic acids described herein. In some embodiments, the host cell is prokaryotic, eukaryotic, mammalian, or human.
[0023] In some aspects, the present disclosure provides an engineered nuclease system comprising: (a) any one of the nucleases, Cas enzymes, or fusion endonucleases described herein; and (b) an engineered guide RNA structure configured to form a complex with the endonuclease, the engineered guide RNA structure comprising: a guide RNA configured to hybridize with a target deoxyribonucleic acid sequence; wherein the guide RNA sequence is configured to bind to the endonuclease. In some embodiments, the guide RNA further comprises a tracr RNA sequence configured to bind to the endonuclease. In some embodiments, the endonuclease is derived from an uncultured microorganism. In some embodiments, the endonuclease is not a Cas9 endonuclease, a Cas14 endonuclease, a Cas12a endonuclease, a Cas12b endonuclease, a Cas 12c endonuclease, a Cas12d endonuclease, a Cas12e endonuclease, a Cas13a endonuclease, a Cas13b endonuclease, a Cas13c endonuclease, or a Cas13d endonuclease. In some embodiments, the endonuclease has less than 86% identity to a SpyCas9 endonuclease. In some embodiments, the system further comprises Mg 2+ In some embodiments, the endonuclease comprises a sequence having at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOs: 8-12, 26-27, or 108, or a variant thereof. In some embodiments, the guide ribonucleic acid sequence comprises a sequence that is at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the non-degenerate nucleotides of any one of SEQ ID NOs: 33, 34, 44, 45, 78, 84, or 87.
[0024] In some aspects, the present disclosure provides an engineered nuclease comprising: (a) 2 Class II Type Cas enzyme RuvC or HNH domains having at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the RuvC or HNH domain of any one of SEQ ID NOs: 1-27, 108, or 109-110, or variants thereof; and (b) 2 Class II Type Cas enzyme PAM interacting (PI) domains having at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the RuvC or HNH domain of any one of SEQ ID NOs: 1-27, 108, or 109-110, or variants thereof; NO: 1-27, 108 or 109-110 any one or its variant PAM interaction (PI) domain has at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity. In some embodiments, (a) and (b) do not exist together naturally. In some embodiments, the 2 class II type Cas enzymes are derived from uncultured microorganisms. In some embodiments, the endonuclease has less than 86% identity to the SpyCas9 endonuclease. In some embodiments, the engineered nuclease comprises a sequence having at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOs: 1-27 or a variant thereof.
[0025] In some aspects, the present disclosure provides an engineered nuclease system comprising: (a) any of the endonucleases described herein; and (b) an engineered guide RNA structure configured to form a complex with the endonuclease, the engineered guide RNA structure comprising: a guide RNA sequence configured to hybridize to a target deoxyribonucleic acid sequence and to bind to the endonuclease. In some embodiments, the guide RNA further comprises a tracr RNA sequence configured to bind to the endonuclease. In some embodiments, the guide RNA sequence comprises a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the non-degenerate nucleotides of any of SEQ ID NOs: 28-32 or 33-44 or variants thereof. In some embodiments, the system further comprises a PAM sequence compatible with the nuclease adjacent to the target nucleic acid site. In some embodiments, the PAM sequence is located 3' to the target deoxyribonucleic acid sequence. In some embodiments, the PAM sequence is located 5' to the target deoxyribonucleic acid sequence.
[0026] In some aspects, the present disclosure provides a method of targeting an albumin gene, the method comprising introducing any of the systems described herein into a cell, wherein the guide ribonucleic acid sequence is configured to hybridize to a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOs: 67-86. In some embodiments, introducing into the cell further comprises contacting the cell with a nucleic acid or vector encoding the fusion protein or the guide polynucleotide, or contacting the cell with a lipid nanoparticle (LNP) comprising the vector or nucleic acid. In some embodiments, introducing into the cell further comprises contacting the cell with a ribonucleoprotein complex (RNP) comprising the fusion protein or the guide polynucleotide, or comprises contacting the cell with a lipid nanoparticle (LNP) comprising the RNP.
[0027] In some aspects, the present disclosure provides a method of targeting an HAO1 gene or locus, the method comprising introducing any of the systems described herein into a cell, wherein the guide ribonucleic acid sequence is configured to hybridize to a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOs: 611-633. In some embodiments, the guide ribonucleic acid sequence is configured to hybridize to a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NO:615, 618, 620, 624, or 626. In some embodiments, the guide ribonucleic acid comprises a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOs: 605-610 or 1789-1865. In some embodiments, the guide RNA comprises a sequence that is at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 1812-1824, 1835, 1849, 1858, or 1861, or a sequence that is at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 1812-1824, 1835, 1849, 1858, or 1861. The targeting sequence of any one of NOs: 1812-1824, 1835, 1849, 1858 or 1861 has a sequence that is at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical.In some embodiments, introducing into the cell further comprises contacting the cell with a nucleic acid or vector encoding the fusion protein or the guide polynucleotide, or comprises contacting the cell with a lipid nanoparticle (LNP) comprising the vector or nucleic acid. In some embodiments, introducing into the cell further comprises contacting the cell with a ribonucleoprotein complex (RNP) comprising the fusion protein or the guide polynucleotide, or comprises contacting the cell with a lipid nanoparticle (LNP) comprising the RNP.
[0028] In some embodiments, the present disclosure provides a method for destroying the HAO-1 locus in a cell, the method comprising introducing into the cell: (a) any of the endonucleases described herein; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease, and the engineered guide RNA comprises a targeting sequence configured to hybridize to a region of the HAO-1 locus, wherein the engineered guide RNA is configured to hybridize to or comprise a targeting sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NOs: 611-633. In some embodiments, the endonuclease is a Class 2, Type II Cas endonuclease. In some embodiments, the 2 class II type Cas endonucleases include any of the fusion or engineered endonucleases described herein. In some embodiments, the endonucleases include any of the fusion or engineered endonucleases described herein. In some embodiments, the 2 class II type Cas endonucleases include a sequence having at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 10 or a variant thereof. In some embodiments, the engineered guide RNA comprises a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the non-degenerate nucleotides of SEQ ID NO: 722.In some embodiments, the engineered guide RNA comprises a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any of SEQ ID NOs: 618, 620, 624, or 626, or a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any of SEQ ID NOs: 618, 620, 624, or 626. The targeting sequence of any of NO: 618, 620, 624 or 626 has a sequence with at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity. In some embodiments, the engineered guide RNA comprises a nucleotide sequence from any of the guide RNAs of Tables 9A-9E, Table 12, Table 18, Table 20 or Table 23. In some embodiments, the engineered guide RNA comprises a nucleotide sequence from any of the guide RNAs of Tables 9A-9E, comprising a chemical modification described in Tables 9A-9E. In some embodiments, the engineered guide RNA comprises a nucleotide sequence from any of the guide RNAs of Tables 12, comprising a chemical modification described in Table 12. In some embodiments, the engineered guide RNA comprises a nucleotide sequence from any one of the guide RNAs of Table 18, said nucleotide sequence comprising the chemical modifications described in Table 18. In some embodiments, the engineered guide RNA comprises a nucleotide sequence from any one of the guide RNAs of Table 20, said nucleotide sequence comprising the chemical modifications described in Table 20. In some embodiments, the engineered guide RNA comprises a nucleotide sequence from any one of the guide RNAs of Table 23, said nucleotide sequence comprising the chemical modifications described in Table 23. In some embodiments, the cell is a mammalian cell. In some embodiments, introducing into the cell further comprises contacting the cell with a nucleic acid or vector encoding the fusion protein or the guide polynucleotide, or comprises contacting the cell with a lipid nanoparticle (LNP) comprising the vector or nucleic acid. In some embodiments, introducing into the cell further comprises contacting the cell with a ribonucleoprotein complex (RNP) comprising the fusion protein or the guide polynucleotide, or comprises contacting the cell with a lipid nanoparticle (LNP) comprising the RNP.
[0029] In some aspects, the disclosure provides a method of disrupting a TRAC locus in a cell, the method comprising introducing into the cell: (a) any of the endonucleases described herein; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a targeting sequence configured to hybridize to a region of the TRAC locus, wherein the engineered guide RNA is configured to hybridize to or comprise a targeting sequence that is at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NOs: 139-158; or wherein the engineered guide RNA comprises a targeting sequence that is at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NOs: 139-158. NO: 119-138 has a sequence of at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity. In some embodiments, the endonuclease is a Class 2 type II Cas endonuclease. In some embodiments, the Class 2 type II Cas endonuclease includes any of the fusion or engineered endonucleases described herein. In some embodiments, the endonuclease includes any of the fusion or engineered endonucleases described herein. In some embodiments, the Class 2 type II Cas endonucleases include any of the fusion endonucleases described herein. In some embodiments, the Class 2 type II Cas endonucleases include a fusion endonuclease with at least 55% identity to SEQ ID NO: 10 or a variant thereof. In some embodiments, the engineered guide RNA comprises a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the non-degenerate nucleotides of SEQ ID NO: 722.In some embodiments, the engineered guide RNA comprises a sequence that is at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 121, 132, 136, 130, 134, 135, or 137, or a sequence that is at least 80% identical to the targeting sequence of any one of SEQ ID NOs: 121, 132, 136, 130, 134, 135, or 137. In some embodiments, the engineered guide RNA comprises the nucleotide sequence of any one of the guide RNAs of Table 9A. In some embodiments, introducing into the cell further comprises contacting the cell with a nucleic acid or vector encoding the fusion protein or the guide polynucleotide, or comprises contacting the cell with a lipid nanoparticle (LNP) comprising the vector or nucleic acid. In some embodiments, introducing into the cell further comprises contacting the cell with a ribonucleoprotein complex (RNP) comprising the fusion protein or the guide polynucleotide, or comprises contacting the cell with a lipid nanoparticle (LNP) comprising the RNP.
[0030] In some embodiments, the present disclosure provides a method of disrupting a B2M locus in a cell, the method comprising introducing into the cell: (a) any of the endonucleases described herein; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a targeting sequence configured to hybridize to a region of the B2M locus, wherein the engineered guide RNA is configured to hybridize to or comprise a targeting sequence that is at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NOs: 185-210; or wherein the engineered guide RNA comprises a targeting sequence that is at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NOs: 185-210. NO: Any one of 159-184 has a sequence of at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity. In some embodiments, the endonuclease is a 2-class II type Cas endonuclease. In some embodiments, the 2-class II type Cas endonuclease includes any one of the fusion or engineered endonucleases described herein. In some embodiments, the endonuclease includes any one of the fusion or engineered endonucleases described herein. In some embodiments, the 2-class II type Cas endonucleases include any fusion endonucleases in the fusion endonucleases described herein. In some embodiments, the 2 Class II type Cas endonucleases comprise a fusion endonuclease comprising a sequence that is at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 10 or a variant thereof.In some embodiments, the engineered guide RNA comprises a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the non-degenerate nucleotides of SEQ ID NO: 722. In some embodiments, the engineered guide RNA comprises a sequence that is at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 159, 165, 168, 174, or 184, or a sequence that is at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: NO: 159, 165, 168, 174 or 184 has a targeting sequence of at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical. In some embodiments, the engineered guide RNA comprises the nucleotide sequence of any one of the guide RNAs of Table 9B. In some embodiments, introducing into the cell further comprises contacting the cell with a nucleic acid or vector encoding the fusion protein or the guide polynucleotide, or comprises contacting the cell with a lipid nanoparticle (LNP) comprising the vector or nucleic acid. In some embodiments, introducing into the cell further comprises contacting the cell with a ribonucleoprotein complex (RNP) comprising the fusion protein or the guide polynucleotide, or comprises contacting the cell with a lipid nanoparticle (LNP) comprising the RNP.
[0031] In some aspects, the present disclosure provides a method of disrupting a TRBC1 locus in a cell, the method comprising introducing into the cell: (a) any of the endonucleases described herein; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a targeting sequence configured to hybridize to a region of the TRBC1 locus, wherein the engineered guide RNA is configured to hybridize to or comprise a targeting sequence that is at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NOs: 252-292; or wherein the engineered guide RNA comprises a targeting sequence that is at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NOs: 252-292. NO: Any one of 211-251 has a sequence of at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity. In some embodiments, the endonuclease is a 2 class II type Cas endonuclease. In some embodiments, the 2 class II type Cas endonucleases include any of the fusion or engineered endonucleases described herein. In some embodiments, the endonuclease includes any of the fusion or engineered endonucleases described herein. In some embodiments, the 2 class II type Cas endonucleases include any of the fusion endonucleases described herein. In some embodiments, the 2 Class II type Cas endonucleases comprise a fusion endonuclease comprising a sequence that is at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 10 or a variant thereof.In some embodiments, the engineered guide RNA comprises a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the non-degenerate nucleotides of SEQ ID NO: 722. In some embodiments, the engineered guide RNA comprises a sequence having at least 80% identity to any one of SEQ ID NOs: 211, 212, 215, 241, or 242, or comprises a targeting sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the targeting sequence of any one of SEQ ID NOs: 211, 212, 215, 241, or 242. In some embodiments, the engineered guide RNA comprises the nucleotide sequence of any one of the guide RNAs of Table 9C. In some embodiments, introducing into the cell further comprises contacting the cell with a nucleic acid or vector encoding the fusion protein or the guide polynucleotide, or comprises contacting the cell with a lipid nanoparticle (LNP) comprising the vector or nucleic acid. In some embodiments, introducing into the cell further comprises contacting the cell with a ribonucleoprotein complex (RNP) comprising the fusion protein or the guide polynucleotide, or comprises contacting the cell with a lipid nanoparticle (LNP) comprising the RNP.
[0032] In some aspects, the present disclosure provides a method of disrupting a TRBC2 locus in a cell, the method comprising introducing into the cell: (a) any of the endonucleases described herein; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a targeting sequence configured to hybridize to a region of the TRBC2 locus, wherein the engineered guide RNA is configured to hybridize to or comprise a targeting sequence that is at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NOs: 338-382; or wherein the engineered guide RNA comprises a targeting sequence that is at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NOs: 338-382. NO: Any one of 293-337 has a sequence of at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity. In some embodiments, the endonuclease is a 2 class II type Cas endonuclease. In some embodiments, the 2 class II type Cas endonucleases include any one of the fusion or engineered endonucleases described herein. In some embodiments, the endonuclease includes any one of the fusion or engineered endonucleases described herein. In some embodiments, the 2 class II type Cas endonucleases are any fusion endonucleases in the fusion endonucleases described herein. In some embodiments, the 2 Class II type Cas endonucleases comprise a fusion endonuclease comprising a sequence that is at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 10 or a variant thereof.In some embodiments, the engineered guide RNA comprises a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the non-degenerate nucleotides of SEQ ID NO: 722. In some embodiments, the engineered guide RNA comprises a sequence that is at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 296, 306, or 332, or comprises a sequence that is at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 296, 306, or 332. NO: 296, 306 or any one of 332 targeting sequences have a targeting sequence of at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity. In some embodiments, the engineered guide RNA comprises the nucleotide sequence of any one of the guide RNAs of Table 9C. In some embodiments, introducing into the cell further comprises contacting the cell with a nucleic acid or vector encoding the fusion protein or the guide polynucleotide, or comprises contacting the cell with a lipid nanoparticle (LNP) comprising the vector or nucleic acid. In some embodiments, introducing into the cell further comprises contacting the cell with a ribonucleoprotein complex (RNP) comprising the fusion protein or the guide polynucleotide, or comprises contacting the cell with a lipid nanoparticle (LNP) comprising the RNP.
[0033] In some aspects, the present disclosure provides a method of disrupting an ANGPTL3 locus in a cell, the method comprising introducing into the cell: (a) any of the endonucleases described herein; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a targeting sequence configured to hybridize to a region of the ANGPTL3 locus, wherein the engineered guide RNA is configured to hybridize to or comprise a targeting sequence having 80% identity to SEQ ID NOs: 478-572; or wherein the engineered guide RNA comprises a targeting sequence having 80% identity to SEQ ID NOs: 478-572. NO: Any one of 383-477 has a sequence of at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity. In some embodiments, the endonuclease is a 2-class II type Cas endonuclease. In some embodiments, the 2-class II type Cas endonuclease includes any one of the fusion or engineered endonucleases described herein. In some embodiments, the endonuclease includes any one of the fusion or engineered endonucleases described herein. In some embodiments, the 2-class II type Cas endonucleases include any fusion endonucleases in the fusion endonucleases described herein. In some embodiments, the 2 Class II type Cas endonucleases comprise fusion endonucleases having at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 10 or a variant thereof. In some embodiments, the engineered guide RNA comprises a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the non-degenerate nucleotides of SEQ ID NO: 722.In some embodiments, the engineered guide RNA comprises a sequence that is at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NO: 419, 425, 431, 439, 447, 453, 461, 467, 471, or 473, or a sequence that is at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NO: NO: 419, 425, 431, 439, 447, 453, 461, 467, 471 or 473 has a sequence of at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity. In some embodiments, the engineered guide RNA comprises the nucleotide sequence of any one of the guide RNAs of Table 9D. In some embodiments, introducing into the cell further comprises contacting the cell with a nucleic acid or vector encoding the fusion protein or the guide polynucleotide, or comprises contacting the cell with a lipid nanoparticle (LNP) comprising the vector or nucleic acid. In some embodiments, introducing into the cell further comprises contacting the cell with a ribonucleoprotein complex (RNP) comprising the fusion protein or the guide polynucleotide, or comprises contacting the cell with a lipid nanoparticle (LNP) comprising the RNP.
[0034] In some aspects, the disclosure provides a method of disrupting a PCSK9 locus in a cell, the method comprising introducing into the cell: (a) any of the endonucleases described herein; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a targeting sequence configured to hybridize to a region of the PCSK9 locus, wherein the engineered guide RNA is configured to hybridize to or comprise a targeting sequence that is at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NOs: 588-602; or wherein the engineered guide RNA comprises a targeting sequence that is at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NOs: 588-602. NO: Any one of 573-587 has a sequence of at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity. In some embodiments, the endonuclease is a 2-class II type Cas endonuclease. In some embodiments, the 2-class II type Cas endonuclease includes any one of the fusion or engineered endonucleases described herein. In some embodiments, the endonuclease includes any one of the fusion or engineered endonucleases described herein. In some embodiments, the 2-class II type Cas endonucleases include any of the fusion endonucleases described herein. In some embodiments, the 2 Class II type Cas endonucleases comprise a fusion endonuclease comprising a sequence that is at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 10 or a variant thereof.In some embodiments, the engineered guide RNA comprises a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the non-degenerate nucleotides of SEQ ID NO: 722. In some embodiments, the engineered guide comprises a sequence that is at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 574, 578, 581, or 585. In some embodiments, the engineered guide RNA comprises the nucleotide sequence of any one of the guide RNAs of Table 9E. In some embodiments, introducing into the cell further comprises contacting the cell with a nucleic acid or vector encoding the fusion protein or the guide polynucleotide, or comprises contacting the cell with a lipid nanoparticle (LNP) comprising the vector or nucleic acid. In some embodiments, introducing into the cell further comprises contacting the cell with a ribonucleoprotein complex (RNP) comprising the fusion protein or the guide polynucleotide, or comprises contacting the cell with a lipid nanoparticle (LNP) comprising the RNP.
[0035] In some embodiments, the present disclosure provides a method of disrupting an albumin locus in a cell, the method comprising introducing into the cell: (a) any of the endonucleases described herein; and (b) an engineered guide RNA, wherein the engineered guide RNA is configured to form a complex with the endonuclease and the engineered guide RNA comprises a targeting sequence configured to hybridize to a region of the albumin locus, wherein the engineered guide RNA comprises a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to any one of SEQ ID NOs: 67-86 or 646-695; or wherein the engineered guide RNA comprises a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to any one of SEQ ID NOs: NO:67-86 or any one of 646-695 has a targeting sequence with at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity. In some embodiments, the endonuclease is a 2 type II type Cas endonuclease. In some embodiments, the 2 type II type Cas endonucleases include any of the fusion or engineered endonucleases described herein. In some embodiments, the endonuclease includes any of the fusion or engineered endonucleases described herein. In some embodiments, the 2 type II type Cas endonucleases include any type II Cas endonucleases in the type II Cas endonucleases described herein. In some embodiments, the 2 Class II type Cas endonucleases comprise fusion endonucleases having at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 10 or a variant thereof.In some embodiments, the engineered guide RNA comprises a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the non-degenerate nucleotides of SEQ ID NO: 722. In some embodiments, the engineered guide RNA is complementary to or comprises a sequence that is at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any of SEQ ID NOs: 67, 68, 70, 71, 72, 76, 79, 80, 647, 648, 649, 653, 654, 655, 656, 673, 680, 681, or 682. In some embodiments, the engineered guide RNA comprises the nucleotide sequence of any one of the guide RNAs of Table 6. In some embodiments, introducing into the cell further comprises contacting the cell with a nucleic acid or vector encoding the fusion protein or the guide polynucleotide, or comprises contacting the cell with a lipid nanoparticle (LNP) comprising the vector or nucleic acid. In some embodiments, introducing into the cell further comprises contacting the cell with a ribonucleoprotein complex (RNP) comprising the fusion protein or the guide polynucleotide, or comprises contacting the cell with a lipid nanoparticle (LNP) comprising the RNP.
[0036] In some aspects, the present disclosure provides an endonuclease comprising an engineered amino acid sequence having at least 55% sequence identity to any one of SEQ ID NOs: 1-27, 108, or 109-110, or a variant thereof.
[0037] In some aspects, the present disclosure provides an engineered nuclease system comprising an endonuclease as described herein and an engineered guide RNA structure, wherein the engineered guide RNA structure is configured to form a complex with the endonuclease, and the engineered guide RNA structure comprises: a guide RNA sequence, wherein the guide RNA sequence is configured to hybridize with a target deoxyribonucleic acid sequence; and a tracr RNA sequence, wherein the tracr RNA sequence is configured to bind to the endonuclease. In some embodiments, the endonuclease is derived from an uncultured microorganism. In some embodiments, the endonuclease is not Cas9 endonuclease, Cas14 endonuclease, Cas12a endonuclease, Cas12b endonuclease, Cas 12c endonuclease, Cas12d endonuclease, Cas12e endonuclease, Cas13a endonuclease, Cas13b endonuclease, Cas13c endonuclease, or Cas13d endonuclease. In some embodiments, the endonuclease has less than 86% identity to the SpyCas9 endonuclease. In some embodiments, the system further comprises MG 2+ Source.
[0038] In some aspects, the present disclosure provides an engineered nuclease comprising: (a) 2 class II type Cas enzymes RuvC and HNH domains having at least 55% sequence identity to the RuvC and HNH domains of any one of SEQ ID NOs: 1-27, 108, or 109-110; and (b) 2 class II type Cas enzymes PAM interaction (PI) domains having at least 55% sequence identity to the PAM interaction (PI) domains of any one of SEQ ID NOs: 1-27, 108, or 109-110. In some embodiments, (a) and (b) do not exist together naturally. In some embodiments, the 2 class II type Cas enzymes are derived from uncultured microorganisms. In some embodiments, the endonuclease has less than 86% identity to the SpyCas9 endonuclease. In some embodiments, the engineered nuclease comprises a sequence having at least 55% sequence identity to any one of SEQ ID NOs: 1-27.
[0039] In some aspects, the present disclosure provides an engineered nuclease system comprising: an endonuclease according to any one of the aspects or embodiments described herein; and an engineered guide RNA structure configured to form a complex with the endonuclease, the engineered guide RNA structure comprising: a guide RNA sequence configured to hybridize with a target deoxyribonucleic acid sequence; and a tracr RNA sequence configured to bind to the endonuclease. In some embodiments, the guide RNA sequence comprises a sequence having at least 80% sequence identity to a non-degenerate nucleotide sequence of any one of SEQ ID NOs: 28-32 or 33-44 or a variant thereof. In some embodiments, the system further comprises a PAM sequence compatible with the nuclease adjacent to the target nucleic acid site. In some embodiments, the PAM sequence is located 3' to the target deoxyribonucleic acid sequence.
[0040] In some embodiments, the present disclosure provides an engineered single-molecule heterologous guide polynucleotide that is compatible with a Class 2, Type II enzyme according to any one of the aspects or embodiments described herein, wherein the heterologous guide polynucleotide comprises a chemical modification according to any one of SEQ ID NOs: 605-610 or 1789-1865.
[0041] In some aspects, the present disclosure provides a method of targeting an albumin gene, the method comprising introducing into a cell a system according to any one of the aspects or embodiments described herein, wherein the guide ribonucleic acid sequence is configured to hybridize to a sequence comprising any one of SEQ ID NOs: 67-86.
[0042] In some aspects, the present disclosure provides a method for targeting the HAO1 gene, the method comprising introducing a system according to any one of the aspects or embodiments described herein into a cell, wherein the guide ribonucleic acid sequence is configured to hybridize with any one of SEQ ID NOs: 611-633. In some embodiments, the guide ribonucleic acid sequence is configured to hybridize with any one of SEQ ID NOs: 615, 618, 620, 624, or 626. In some embodiments, the guide ribonucleic acid comprises a sequence according to any one of SEQ ID NOs: 605-610 or 1789-1865. In some embodiments, the guide ribonucleic acid comprises a sequence according to any one of SEQ ID NOs: 1812-1824, 1835, 1849, 1858, or 1861.
[0043] In some aspects, the disclosure provides cells comprising endonucleases described herein. In some aspects, the disclosure provides cells comprising any nucleic acid molecule described herein. In some aspects, the disclosure provides cells comprising engineered nuclease systems described herein.
[0044] In certain embodiments, the present invention describes an engineered endonuclease comprising: a) an N-terminal portion comprising a sequence having at least 80% sequence identity to SEQ ID NO: 696; and b) a C-terminal portion comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 697-721. In some embodiments, the N-terminal portion and the C-terminal portion are directly fused to each other. In some embodiments, the N-terminal portion and the C-terminal portion are joined by a linker. In some embodiments, the linker is a glycine and / or serine-rich linker, a large protein domain, a long helical structure, or a short helical structure. In some embodiments, the linker is (GGGGS)n, and wherein n is an integer from 1 to 20. In some embodiments, the linker is GGGGS (SEQ ID NO: 2864). In some embodiments, the N-terminal portion comprises a sequence having at least 90% sequence identity to SEQ ID NO: 696. In some embodiments, the N-terminal portion comprises a sequence having 100% sequence identity to SEQ ID NO: 696. In some embodiments, the C-terminal portion comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 697-721. In some embodiments, the C-terminal portion comprises a sequence having 100% sequence identity to any one of SEQ ID NOs: 697-721. In some embodiments, the engineered endonuclease is configured to bind to a PAM comprising any one of SEQ ID NOs: 60-66, 117, 865-919, and 2855-2863.
[0045] In certain embodiments, described herein are engineered endonucleases comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862. In some embodiments, the engineered endonucleases comprise a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862. In some embodiments, the engineered endonucleases comprise a sequence having 100% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862.
[0046] In certain embodiments, described herein are engineered endonucleases comprising a sequence having at least 80% sequence identity to SEQ ID NO: 10. In some embodiments, the engineered endonucleases comprise a sequence having at least 90% sequence identity to SEQ ID NO: 10. In some embodiments, the engineered endonucleases comprise a sequence having 100% sequence identity to SEQ ID NO: 10.
[0047] In certain embodiments, described herein are engineered endonucleases comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 109-110 and 2842-2854. In some embodiments, the engineered endonucleases comprise a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 109-110 and 2842-2854. In some embodiments, the engineered endonucleases comprise a sequence having 100% sequence identity to any one of SEQ ID NOs: 109-110 and 2842-2854.
[0048] In certain embodiments, described herein are engineered nuclease systems comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the endonuclease and hybridize to a target nucleic acid sequence. In some embodiments, the engineered endonuclease comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862. In some embodiments, the engineered endonuclease comprises a sequence having 100% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862. In some embodiments, the engineered guide polynucleotide is a single guide nucleic acid. In some embodiments, the engineered guide polynucleotide is a dual guide nucleic acid. In some embodiments, the engineered guide polynucleotide is RNA. In some embodiments, the engineered endonuclease non-covalently binds to the engineered guide polynucleotide. In some embodiments, the endonuclease is covalently linked to the engineered guide polynucleotide. In some embodiments, the endonuclease is fused to the engineered guide polynucleotide. In some embodiments, the engineered guide polynucleotide comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 28-45, 605-610, 646-695, 863, and 1789-1826. In some embodiments, the engineered guide polynucleotide comprises a sequence having 100% sequence identity to any one of SEQ ID NOs: 28-45, 605-610, 646-695, 863, and 1789-1826. In some embodiments, the engineered endonuclease is configured to bind to a PAM comprising any one of SEQ ID NOs: 60-66, 865-919, and 2863.
[0049] In certain embodiments, an engineered nuclease system is described herein, comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 109-110 and 2842-2854; and b) an engineered guide polynucleotide configured to form a complex with the endonuclease and hybridize to a target nucleic acid sequence. In some embodiments, the engineered endonuclease comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 109-110 and 2842-2854. In some embodiments, the engineered endonuclease comprises a sequence having 100% sequence identity to any one of SEQ ID NOs: 109-110 and 2842-2854. In some embodiments, the engineered guide polynucleotide is a single guide nucleic acid. In some embodiments, the engineered guide polynucleotide is a dual guide nucleic acid. In some embodiments, the engineered guide polynucleotide is RNA. In some embodiments, the engineered endonuclease is non-covalently bound to the engineered guide polynucleotide. In some embodiments, the endonuclease is covalently linked to the engineered guide polynucleotide. In some embodiments, the endonuclease is fused to the engineered guide polynucleotide. In some embodiments, the engineered guide polynucleotide comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 111-113. In some embodiments, the engineered guide polynucleotide comprises a sequence having 100% sequence identity to any one of SEQ ID NOs: 111-113. In some embodiments, the engineered endonuclease is configured to bind to a PAM comprising any one of SEQ ID NOs: 117 and 2855-2862.
[0050] In certain embodiments, described herein are engineered nuclease systems comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within an albumin gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 67-86.
[0051] In certain embodiments, described herein are engineered nuclease systems comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a TRAC gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617. In some embodiments, the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 139-158, 925-927, 992-1011, 1184-1279, 1321-1361, 2486-2581, and 2618-2653.
[0052] In certain embodiments, described herein are engineered nuclease systems comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a B2M gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 159-184. In some embodiments, the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 185-210.
[0053] In certain embodiments, described herein are engineered nuclease systems comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a TRBC1 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 211-251. In some embodiments, the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 252-292.
[0054] In certain embodiments, described herein are engineered nuclease systems comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a TRBC2 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 293-337. In some embodiments, the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 338-382.
[0055] In certain embodiments, described herein are engineered nuclease systems comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within an ANGPTL3 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 383-477, 1392-1489, 2120-2215, and 2312-2350. In some embodiments, the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 478-572, 1490-1587, 2216-2311, and 2351-2389.
[0056] In certain embodiments, described herein are engineered nuclease systems comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a PCSK9 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 573-587 and 1362-1376. In some embodiments, the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 588-602 and 1377-1391.
[0057] In certain embodiments, described herein are engineered nuclease systems comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a VCP gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 723-738 and 755-762. In some embodiments, the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 739-754 and 763-770.
[0058] In certain embodiments, described herein are engineered nuclease systems comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the AAVS1 locus or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 928-949 and 1012-1049. In some embodiments, the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 950-971 and 1050-1087.
[0059] In certain embodiments, described herein are engineered nuclease systems comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a GPR146 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1588-1656. In some embodiments, the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1657-1725.
[0060] In certain embodiments, described herein are engineered nuclease systems comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within an APOA1 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1726-1744, 1764-1774, 1866-1961, and 2058-2088. In some embodiments, the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1745-1763, 1775-1785, 1962-2057, and 2089-2119.
[0061] In certain embodiments, described herein are engineered nuclease systems comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a HAO1 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 611-633, 1789-1826, and 1827-1865.
[0062] In certain embodiments, described herein are methods for modifying a target nucleic acid sequence, comprising contacting the target nucleic acid sequence using an endonuclease described herein or an engineered nuclease system described herein. In some embodiments, the modification of the target nucleic acid sequence comprises binding to the target nucleic acid sequence, nicking the target nucleic acid sequence, or cutting the target nucleic acid sequence. In some embodiments, the target nucleic acid sequence comprises genomic DNA, viral DNA, viral RNA, or bacterial DNA. In some embodiments, the modification is in vitro. In some embodiments, the modification is in vivo. In some embodiments, the modification is ex vivo. In some embodiments, gRNA is encoded by a sequence having any one of SEQ ID NOs: 251-260, 271-274, and 279-290. In some embodiments, the target nucleic acid sequence comprises a sequence having any one of SEQ ID NOs: 261-270, 275-278, and 291-302.
[0063] In certain embodiments, described herein are methods for modifying a target nucleic acid sequence in a mammalian cell, the method comprising contacting the mammalian cell with an endonuclease as described herein or an engineered nuclease system as described herein. In some embodiments, the method further comprises selecting a cell comprising the modification.
[0064] In certain embodiments, described herein are methods of modifying an albumin gene, the method comprising contacting the albumin gene with an engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the albumin gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 67-86.
[0065] In certain embodiments, described herein are methods of modifying a TRAC gene, the method comprising contacting the TRAC gene with an engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the TRAC gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617. In some embodiments, the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 139-158, 925-927, 992-1011, 1184-1279, 1321-1361, 2486-2581, and 2618-2653.
[0066] In certain embodiments, described herein are methods of modifying a B2M gene, the methods comprising contacting the B2M gene with an engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the B2M gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 159-184. In some embodiments, the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 185-210.
[0067] In certain embodiments, described herein are methods of modifying a TRBC1 gene, the methods comprising contacting the TRBC1 gene with an engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the TRBC1 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 211-251. In some embodiments, the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 252-292.
[0068] In certain embodiments, described herein are methods of modifying a TRBC2 gene, the methods comprising contacting the TRBC2 gene with an engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the TRBC2 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 293-337. In some embodiments, the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 338-382.
[0069] In certain embodiments, described herein are methods of modifying an ANGPTL3 gene, the method comprising contacting the ANGPTL3 gene with an engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the ANGPTL3 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 383-477, 1392-1489, 2120-2215, and 2312-2350. In some embodiments, the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 478-572, 1490-1587, 2216-2311, and 2351-2389.
[0070] In certain embodiments, described herein are methods of modifying a PCSK9 gene, the methods comprising contacting the PCSK9 gene with an engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the PCSK9 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 573-587 and 1362-1376. In some embodiments, the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 588-602 and 1377-1391.
[0071] In certain embodiments, described herein are methods of modifying a VCP gene, the methods comprising contacting the VCP gene with an engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the VCP gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 723-738 and 755-762. In some embodiments, the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 739-754 and 763-770.
[0072] In certain embodiments, described herein are methods of modifying an AAVS1 locus, the methods comprising contacting the AAVS1 locus with an engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the AAVS1 locus or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 928-949 and 1012-1049. In some embodiments, the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 950-971 and 1050-1087.
[0073] In certain embodiments, described herein are methods of modifying a GPR146 gene, the methods comprising contacting the GPR146 gene with an engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the GPR146 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1588-1656. In some embodiments, the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1657-1725.
[0074] In certain embodiments, described herein are methods of modifying an APOA1 gene, the method comprising contacting the APOA1 gene with an engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the APOA1 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1726-1744, 1764-1774, 1866-1961, and 2058-2088. In some embodiments, the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1745-1763, 1775-1785, 1962-2057, and 2089-2119.
[0075] In certain embodiments, described herein are methods of modifying a TRAC gene, the method comprising contacting the TRAC gene with an engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the HAO1 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 611-633, 1789-1826, and 1827-1865.
[0076] In certain embodiments, cells comprising the endonucleases described herein or the engineered nuclease systems described herein are described herein. In some embodiments, the cells are eukaryotic cells. In some embodiments, the cells are mammalian cells. In some embodiments, the cells are immortalized cells. In some embodiments, the cells are insect cells. In some embodiments, the cells are yeast cells. In some embodiments, the cells are plant cells. In some embodiments, the cells are fungal cells. In some embodiments, the cells are prokaryotic cells. In some embodiments, the cells are A549, HEK-293, HEK-293T, BHK, CHO, HeLa, MRC5, Sf9, Cos-1, Cos-7, Vero, BSC 1, BSC 40, BMT 10, WI38, HeLa, Saos, C2C12, L cells, HT1080, HepG2, Huh7, K562, primary cells, or derivatives thereof. In some embodiments, the cells are engineered cells. In some embodiments, the cells are stable cells.
[0077] For those skilled in the art, further aspects and advantages of the present disclosure will become apparent from the following detailed description, wherein only illustrative embodiments of the present disclosure are shown and described. As will be appreciated, the present disclosure is capable of other and different embodiments, and its several details are capable of modification in various obvious respects, all without departing from the present disclosure. Accordingly, the drawings and description are to be regarded as illustrative in nature and not restrictive. BRIEF DESCRIPTION OF THE DRAWINGS
[0078] The novel features of the present disclosure are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description which sets forth illustrative embodiments in which the principles of the present disclosure are utilized, and in the accompanying drawings (also referred to herein as "Figures"):
[0079] Figures 1A-1B The native PAM specificities of the various effectors described herein are depicted. Figure 1A Shown is a phylogenetic tree of the various effectors described herein. Figure 1B is a table of PAM specificities of natural RNA-guided CRISPR-associated endonucleases.
[0080] Figure 2 Demonstrated the concept of domain exchange between RNA-guided CRISPR-associated nucleases.
[0081] Figure 3A and 3B An alignment of multiple sequences is depicted to guide the determination of optimal breakpoints. Figure 3A SaCas9 and SpCas9 are shown aligned with several proteins described herein, and the terminal conserved residue (alanine residue) of these sequences is identified as the proposed C-terminus of the exchange segment. Figure 3B The C-terminal domain of the SaCas9 protein is depicted as a swapped span of the RuvC-III, WED, TOPO, and CTD domains. The PAM interaction domain is composed of the TOPO and CTD domains. The swapped C-terminal domain does not contain active site residues (D10, E477, and H701 of the RuvC domain and D556, D557, and N580 of the NHN domain).
[0082] Figure 4 Depicts screening of chimeras by in vitro PAM enrichment assay when MG3-6 is recombined with various C-terminal domains from closely and distantly related nucleases. sgRNAs derived from the N-terminal parental domains are used for RNA-guided nuclease activity.
[0083] Figures 5A-5B The PAM sequences of the functional chimeras described herein are depicted ( Figure 5A ) and SeqLogo depiction of PAM sequences ( Figure 5B Given breakpoint swapping of the predicted C-terminal domains of RuvC-III, WED, TOPO, and CTD, the chimeras were functional when recombined with closely related nucleases. Even when the native protein was not functional in the same assay, the engineered chimeras tended to retain the PAM specificity of the native protein's PAM-interacting domain.
[0084] Figure 6 Shown is the screening of chimeras recombining MG3-6 with various C-terminal domains from closely and distantly related nucleases by an in vitro PAM enrichment assay. sgRNAs derived from the C-terminal parental domain were used for RNA-guided nuclease activity. Numbers in parentheses indicate sgRNA species. There was no rescue activity using sgRNAs derived from the C-terminal parental domain.
[0085] Figure 7 The predicted structures of MG3-6 and MG15-1 are shown. The WED and PI domains of MG3-6 were swapped with those of their MG15-1 counterparts to generate chimera 1 (C1). Alternatively, the PI domain of MG3-6 was swapped with its MG15-1 counterpart to generate chimera 2 (C2).
[0086] Figures 8A-8B Depicted are the results of an in vitro PAM enrichment assay and Sanger sequencing for PAM specificity. C1: MG3-6 + MG15-1 (WP) and C2: MG3-6 + MG15-1 (P). The engineered chimeras tend to retain the PAM specificity of the native protein's PAM interaction domain. The PAM enrichment assay was performed in triplicate. ( Figure 8A ) shows an agarose gel depiction of an assay demonstrating that the sequence is cleaved in the presence of active enzyme, and ( Figure 8B ) shows the SeqLogo description of the PAM sequence determined by the assay.
[0087] Figures 9A-9B Depict the activity of the chimeras described herein in mammalian cells. Chimera-encoding mRNA was co-transfected with 20 different sgRNAs (see, e.g., SEQ ID NOs: 67-86) into Hepa 1-6 cells. Editing was assessed by Sanger sequencing and CRISPR editing inference (ICE). Figure 9A The editing efficiency of the tested guides is shown. Two biological replicates are shown. Figure 9B Indel curves created by representative guides are shown.
[0088] Figure 10 Depicted are the results of guide screening in Hepa1-6 cells; guides were delivered as mRNA and gRNA using lipofectamine Messenger Max.
[0089] Figure 11A Depicted are the structural sections of the MG3-6 / 3-4 guide.
[0090] Figure 11BDepicted are the structural parts of the MG3-6 guide.
[0091] Figure 12 Depicted are the activity of chemically modified MG3-6 / 3-4 guides in Hepa1-6 cells when delivered using lipofectamine Messenger Max as both mRNA and gRNA.
[0092] Figure 13 Depicted is the stability of the chemically modified MG3-6 / 3-4 guide at 37°C over 9 hours.
[0093] Figure 14 Depicted is the stability of the chemically modified MG3-6 / 3-4 guide at 37°C over 21 hours.
[0094] Figures 15A-15B In vitro screening of type VA chimeras is depicted. Figure 15A Agarose gels depicting the amplified cleavage products of each cleavage reaction are shown. Positive enrichment was observed with the MG29-1+MG29-5 chimera, domain-swapped from the same family (numbers in brackets indicate sgRNA species). Figure 15B Seqlogo depictions of the PAMs for the parent enzyme and chimeras derived therefrom are depicted.
[0095] Figure 16 Depicts the gene editing results of TRAC at the DNA level in HEK293T cells.
[0096] Figure 17 Depicts the results of B2M gene editing at the DNA level in HEK293T cells.
[0097] Figure 18 Depicted are the consequences of TRAC gene editing in T cells at the DNA and phenotypic levels.
[0098] Figure 19 Depicts the results of gene editing of B2M at the DNA level in T cells.
[0099] Figure 20 Depicts the phenotypic consequences of gene editing of TRBC1 and TRBC2 in T cells.
[0100] Figure 21 Depicts the results of gene editing of ANGPTL3 at the DNA level in Hep3B cells.
[0101] Figure 22 Depicts the results of PCSK9 gene editing at the DNA level in Hep3B cells.
[0102] Figure 23Depicts genome editing of MG3-6 / 3-4 at the HAO-1 locus in wild-type mice analyzed by next-generation sequencing.
[0103] Figure 24 Depicted are glycolate oxidase protein levels in the livers of mice treated with MG3-6 / 3-4 mRNA and a guide RNA targeting the HAO-1 gene.
[0104] Figure 25 Depicted are genome editing at the HAO-1 locus in wild-type mice treated with MG3-6 / 3-4 mRNA and guide RNA 7 (G7) targeting HAO-1 with four different chemical modifications.
[0105] Figure 26 Depicted are Western blot analyses of glycolate oxidase (GO) / HAO-1 protein levels in mouse livers at day 11 after treatment with LNPs encapsulating MG3-6 / 3-4 mRNA and sgRNA 7 (G7) with four different chemical modifications, as described in Example 19. Individual mice are represented by numbers.
[0106] Figure 27 Depicted are the activity of chemically modified guides in Hep3B cells when delivered using lipofection as mRNA and gRNA to target HAO-1, as in Example 20.
[0107] Figure 28 Depicted are the activity of chemically modified guides in primary human hepatocytes when delivered using lipofection for mRNA and gRNA targeting HAO-1, as described in Example 21.
[0108] Figure 29 Demonstration of mammalian cell editing and determination of the PAM sequences of two MG3-6 chimeric enzymes, as evaluated in Example 22, are depicted.
[0109] Figure 30 Depicted is the evaluation of MG3-6 / 3-4 guide chemical editing activity in mouse liver following in vivo delivery in LNPs, as in Example 23.
[0110] Figure 31 The results of gene editing of VCP at the DNA level in K562 cells are depicted, as in Example 24.
[0111] Figure 32 Depicts the results of DNA-level gene editing in K562 cells. Guides were designed to target TRAC and AAVS1. MG3-6_3-3RWP is a chimera that swaps portions of RuvC III, WED, and PID of MG3-6 with MG3-3.
[0112] Figure 33 Depicts the results of DNA-level gene editing in K562 cells. Guides were designed to target TRAC and AAVS1. MG3-6_3-7RWP is a chimera that swaps portions of RuvC III, WED, and PID in MG3-6 with MG3-7.
[0113] Figure 34 Depicts the results of DNA-level gene editing in K562 cells. The guide was designed to target TRAC. MG3-6_3-8RWP is a chimera that swaps portions of RuvC III, WED, and PID of MG3-6 with MG3-8.
[0114] Figure 35 Depicts the results of DNA-level gene editing in K562 cells. The guide was designed to target TRAC. MG3-6_3-8RWP is a chimera that swaps portions of RuvC III, WED, and PID of MG3-6 with MG3-8.
[0115] Figure 36 Depicts the results of DNA-level gene editing in human Hep3B cells. The guide was designed to target PCSK9. MG3-6_3-4RWP is a chimera that swaps portions of RuvC III, WED, and PID of MG3-6 with MG3-4.
[0116] Figure 37 Depicts the results of DNA-level gene editing in human Hep3B cells. The guide was designed to target ANGPTL3. MG3-6_3-4RWP is a chimera that swaps portions of RuvC III, WED, and PID of MG3-6 with MG3-4.
[0117] Figure 38 Depicts the results of DNA-level gene editing in human Hep3B cells. The guide was designed to target APOA1. MG3-6_3-8RWP is a chimera that swaps portions of RuvC III, WED, and PID from MG3-6 with MG3-8.
[0118] Figure 39 Depicts the results of DNA-level gene editing in mouse Hepa1-6 cells. The guide was designed to target GPR146. MG3-6_3-7RWP is a chimera that swaps portions of RuvC III, WED, and PID of MG3-6 with MG3-7RWP.
[0119] Figure 40Depicts the results of DNA-level gene editing in mouse Hepa1-6 cells. The guide was designed to target APOA1. MG3-6_3-4RWP is a chimera that swaps portions of RuvC III, WED, and PID of MG3-6 with MG3-4.
[0120] Figure 41 The design strategy of the MG3-6 chimera is depicted. Figure 41 Panel (a) (top left) depicts the predicted domain boundaries of MG3-6 and the breakpoints for recombination with MG3 and MG150 members. Figure 41 Panel (b) (lower left) depicts the predicted 3D structure of MG3-6 and the breakpoints of protein reassembly. The structure was predicted by Novafold. Figure 41 Panel (c) (right) depicts a multiple sequence alignment (MSA) of MG3 and MG150 members. Breakpoints are indicated by arrows.
[0121] Figures 42A-42B Screening of MG3-6 chimeras and characterization of PAM specificity are depicted. Figure 42A (Left) Depicts DNA agarose gel electrophoresis analysis to assess enzyme activity. Figure 42B (Right) Phylogenetic tree and Seqlogo depicting functional chimeras.
[0122] Figure 43 The design strategy of the MG3-6_3-8 chimera is depicted. Figure 43 Panel (a) (top left) depicts the predicted domain boundaries of MG3-6_3-8 and the breakpoints for recombination with MG3 and MG150 members. Figure 43 Panel (b) (lower left) depicts the predicted 3D structure of MG3-6 and the breakpoints of protein reassembly. The structure was predicted by Novafold. Figure 43 Panel (c) (middle) depicts the multiple sequence alignment (MSA) of MG3 and MG150 members. Figure 43 Panel (d) (right) depicts a multiple sequence alignment (MSA) of MG15 members. Breakpoints are indicated by arrows.
[0123] Figures 44A-44B Screening of MG3-6_3-8 chimeras and characterization of PAM specificity are depicted. Figure 44A (Top) Depicts DNA agarose gel electrophoresis analysis to assess enzyme activity. Figure 44B (Bottom) Seqlogo consensus depiction of the PAM sequence of the functional chimera.
[0124] Figure 45 Depicted are the structures of exemplary cationic lipids that can be used in the lipid nanoparticles described herein.
[0125] Figure 46 Depicted is the evaluation of HAO-1 gene editing and mRNA knockdown activity of MG3-6 / 3-4 guide chemicals in mouse liver following in vivo delivery in LNPs, as described in Example 28.
[0126] Figure 47 Depicts the results of mApoa1 gene editing at the DNA level in Hepa1-6 cells.
[0127] Figure 48 Depicts the results of gene editing of mAngptl3 at the DNA level in Hepa1-6 cells.
[0128] Figure 49 Depicts the gene editing results of mTrac at the DNA level in Hepa1-6 cells.
[0129] Figure 50 Depicts genome editing at the APOA1 and ANGPTL3 loci by MG3-6 / 3-8 in wild-type mice analyzed by next-generation sequencing.
[0130] Figure 51A Depicted is a phylogenetic tree of the various MG29 effectors described herein. Figure 51B The three-dimensional structure of the MG29-1 effector predicted using Alphafold2 is depicted. The nucleic acids forming the R-loop were modeled by structural alignment with Cpf1 (PDB ID: 5XH7). The REC, RuvC, and NUC domains are colored in gray, cyan, and pink, respectively. The PAM-interacting domains, namely the WED-II, WED-III, and PID domains, are colored in yellow and orange, respectively.
[0131] Figure 52A Depicted is a phylogenetic analysis of type VA nucleases. A phylogenetic tree was inferred using RAxML from a MAFFT global (g-ins-i) multiple sequence alignment. Ancestral WedII, PI, and WedIII domains were generated for three ancestral nodes (nodes highlighted with closed circles: MG29-229, MG29-230, and MG29-231). Figure 52B Depicted are the 3D structure predictions of the ancestral domain from MG29-28 relative to the predicted structure of MG29-1. The high similarity of these domains is observed through the overlap between the structures (top) and the conservation of key residues in the sequence alignment (bottom). Important residues involved in PAM binding are indicated by the dark boxes above the alignment and by stick sketches in the 3D alignment.
[0132] Figure 53A 、 53Band 53C depict multiple sequence alignments of MG29-1 homologs used to determine optimal breakpoints for chimera generation. Figure 53A Depicted are MG29-1 and FnCas12a aligned with several proteins described herein. The WED-II, PID, and WED-III domains are annotated to highlight the domains that are exchanged. Dashed lines depict the cleavage sites used to exchange these enzyme domains. Figure 53B : The C-terminus of MG29-1 protein and its homologs consists of a breakpoint at the edge of the REC domain and the WED-II domain. Figure 53C The N-termini of MG29-1 protein and its homologs consist of breakpoints at the edges of the WED-III and RuvC domains. Overall, the exchanged region spans the WED-II, PID, and WED-III domains.
[0133] Figure 54 In vitro screening of type VA chimeras is depicted. Agarose gel depicts the amplified cleavage products of each cleavage reaction. Positive enrichment was observed for chimeras with MG29-1 and several of its homologs, namely MG29-13, MG29-14, MG29-16, MG29-20, and MG29-18.
[0134] Figure 55 Depicts in vitro screening of VA-type ancestral sequences and their corresponding chimeras using MG29-1. Agarose gel depicts the amplified cleavage products of each cleavage reaction. Positive enrichment was observed only for the ancestral reconstructions MG29-230 and MG29-231. However, all corresponding chimeras were found to be active.
[0135] Figure 56 PAMs associated with chimeras derived from MG29-1 and its chimeras are depicted.
[0136] Brief Description of Sequence Listing
[0137] The sequence listing submitted herewith provides exemplary polynucleotide and polypeptide sequences for use in the methods, compositions and systems according to the present disclosure. Below is an exemplary description of the sequences therein.
[0138] MG3-6 chimera
[0139] SEQ ID NOs: 1-27 and 771-862 show the full-length peptide sequences of the MG3-6 chimeric nuclease.
[0140] SEQ ID NO: 108 shows the nucleotide sequence of MG3-6 / 3-4 nuclease containing a 5'UTR, NLS, CDS, NLS, 3'UTR, and a polyA tail.
[0141] SEQ ID NO: 722 shows the nucleotide sequence of the MG3-6 / 3-4 guide sgRNA scaffold.
[0142] SEQ ID NOs: 28-45, 605-610, 646-695, 863, and 1789-1826 show the nucleotide sequences of sgRNAs engineered to function with the MG3-6 chimeric nuclease.
[0143] SEQ ID NO: 603 shows the DNA coding sequence of MG3-6 / 3-4.
[0144] SEQ ID NO: 604 shows the protein sequence of the MG3-6 / 3-4 cassette coding sequence.
[0145] MG29-1 chimera
[0146] SEQ ID NOs: 109-110 and 2842-2854 show the full-length peptide sequences of the MG29-1 chimeric nuclease.
[0147] SEQ ID NOs: 111-113 show the nucleotide sequences of sgRNAs engineered to function with the MG29-1 chimeric nuclease.
[0148] MG chimera
[0149] SEQ ID NO: 696 shows the N-terminal peptide sequence (1-742) of MG3-6.
[0150] SEQ ID NOs: 697-721 show the C-terminal peptide sequences.
[0151] Albumin targeting
[0152] SEQ ID NOs:67-86 show the nucleotide sequences of sgRNAs engineered to function with MG3-6 / 3-4 nuclease to target albumin.
[0153] TRAC targeting
[0154] SEQ ID NOs: 119-138 show the nucleotide sequences of sgRNAs engineered to function with MG3-6 / 3-4 nuclease to target TRAC.
[0155] SEQ ID NOs: 139-158 show the DNA sequences of the TRAC target sites.
[0156] SEQ ID NOs:922-924 show the nucleotide sequences of sgRNAs engineered to function with the MG3-6 / 3-3 nuclease to target TRAC.
[0157] SEQ ID NOs:925-927 show the DNA sequences of the TRAC target sites.
[0158] SEQ ID NOs:972-991 show the nucleotide sequences of sgRNAs engineered to function with MG3-6 / 3-7 nuclease to target TRAC.
[0159] SEQ ID NOs:992-1011 show the DNA sequences of the TRAC target sites.
[0160] SEQ ID NOs: 1088-1183, 1280-1320, 2390-2485, and 2582-2617 show the nucleotide sequences of sgRNAs engineered to function with the MG3-6 / 3-8 nuclease to target TRAC.
[0161] SEQ ID NOs: 1184-1279, 1321-1361, 2486-2581, and 2618-2653 show the DNA sequences of the TRAC target sites.
[0162] B2M Targeting
[0163] SEQ ID NOs: 159-184 show the nucleotide sequences of sgRNAs engineered to function with MG3-6 / 3-4 nuclease to target B2M.
[0164] SEQ ID NOs: 185-210 show the DNA sequences of the B2M target sites.
[0165] TRBC1 targeting
[0166] SEQ ID NOs: 211-251 show the nucleotide sequences of sgRNAs engineered to function with MG3-6 / 3-4 nuclease to target TRBC1.
[0167] SEQ ID NOs: 252-292 show the DNA sequences of the TRBC1 target sites.
[0168] TRBC2 targeting
[0169] SEQ ID NOs: 293-337 show the nucleotide sequences of sgRNAs engineered to function with the MG3-6 / 3-4 nuclease to target TRBC2.
[0170] SEQ ID NOs: 338-382 show the DNA sequences of the TRBC2 target sites.
[0171] ANGPTL3 targeting
[0172] SEQ ID NOs: 383-477 and 1392-1489 show the nucleotide sequences of sgRNAs engineered to function with the MG3-6 / 3-4 nuclease to target ANGPTL3.
[0173] SEQ ID NOs: 478-572 and 1490-1587 show the DNA sequences of the ANGPTL3 target sites.
[0174] SEQ ID NOs: 2120-2215 and 2312-2350 show the nucleotide sequences of sgRNAs engineered to function with the MG3-6 / 3-8 nuclease to target ANGPTL3.
[0175] SEQ ID NOs: 2216-2311 and 2351-2389 show the DNA sequences of the ANGPTL3 target sites.
[0176] PCSK9 targeting
[0177] SEQ ID NOs: 573-587 and 1362-1376 show the nucleotide sequences of sgRNAs engineered to function with MG3-6 / 3-4 nuclease to target PCSK9.
[0178] SEQ ID NOs: 588-602 and 1377-1391 show the DNA sequences of the PCSK9 target sites.
[0179] VCP R155 targeting
[0180] SEQ ID NOs:723-738 show the nucleotide sequences of sgRNAs engineered to function with MG3-6 / 3-8 nuclease to target VCP R155.
[0181] SEQ ID NOs: 739-754 show the DNA sequences of the VCPR155 target sites.
[0182] SEQ ID NOs:755-762 show the nucleotide sequences of sgRNAs engineered to function with MG3-6 / 3-4 nuclease to target VCP R155.
[0183] SEQ ID NOs: 763-770 show the DNA sequences of the VCPR155 target sites.
[0184] AAVS1 targeting
[0185] SEQ ID NOs:928-949 show the nucleotide sequences of sgRNAs engineered to function with MG3-6 / 3-3 nuclease to target AAVS1.
[0186] SEQ ID NOs: 950-971 show the DNA sequences of the AAVS1 target sites.
[0187] SEQ ID NOs: 1012-1049 show the nucleotide sequences of sgRNAs engineered to function with MG3-6 / 3-7 nucleases to target AAVS1.
[0188] SEQ ID NOs: 1050-1087 show the DNA sequences of the AAVS1 target sites.
[0189] GPR146 targeting
[0190] SEQ ID NOs: 1588-1656 show the nucleotide sequences of sgRNAs engineered to function with the MG3-6 / 3-7 nuclease to target M. musculus GPR146.
[0191] SEQ ID NOs: 1657-1725 show the DNA sequences of the Mus musculus GPR146 target sites.
[0192] APOA1 targeting
[0193] SEQ ID NOs: 1726-1744 show the nucleotide sequences of sgRNAs engineered to function with MG3-6 / 3-4 nucleases to target Mus musculus APOA1.
[0194] SEQ ID NOs: 1745-1763 show the DNA sequences of the Mus musculus APOA1 target sites.
[0195] SEQ ID NOs: 1764-1774 show the nucleotide sequences of sgRNAs engineered to function with the MG3-6 / 3-4 nuclease to target H. sapiens APOA1.
[0196] SEQ ID NOs: 1775-1785 show the DNA sequences of the Homo sapiens APOA1 target sites.
[0197] SEQ ID NOs: 1866-1961 and 2058-2088 show the nucleotide sequences of sgRNAs engineered to function with MG3-6 / 3-8 nuclease to target mouse APOA1.
[0198] SEQ ID NOs: 1962-2057 and 2089-2119 show the DNA sequences of mouse APOA1 target sites.
[0199] HAO1 targeting
[0200] SEQ ID NOs: 611-633 and 1789-1826 show the nucleotide sequences of sgRNAs engineered to function with MG3-6 / 3-4 nuclease to target Mus musculus HAO1.
[0201] SEQ ID NOs: 1827-1865 show the nucleotide sequences of sgRNAs engineered to function with MG3-6 / 3-4 nuclease to target human HAO1.
[0202] Other sequences
[0203] SEQ ID NOs: 87-102, 118, 634-645, and 1786-1787 show primer sequences.
[0204] SEQ ID NOs: 103-107, 920-921 and 1788 show the plasmid sequences. DETAILED DESCRIPTION
[0205] Although various embodiments of the present disclosure have been shown and described herein, it will be apparent to those skilled in the art that these embodiments are provided by way of example only. Various variations, modifications, and substitutions may occur to those skilled in the art without departing from the present disclosure. It should be understood that various alternatives to the embodiments of the present disclosure described herein may be employed.
[0206] The practice of some of the methods disclosed herein employs, unless otherwise indicated, techniques of immunology, biochemistry, chemistry, molecular biology, microbiology, cell biology, genomics and recombinant DNA. See, e.g., Sambrook and Green et al., Molecular Cloning: A Laboratory Manual, 4th ed. (2012); the series Current Protocols in Molecular Biology (FM Ausubel et al., eds.); the series Methods In Enzymology (Academic Press, Inc.), PCR 2: A Practical Approach (MJ MacPherson, BD Hames and GR Taylor, eds. (1995)); Harlow and Lane, eds. (1988) Antibodies, A Laboratory Manual; and Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications, 6th ed. (RI Freshney, ed., (2010)).
[0207] As used herein, the singular forms "a / an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. In addition, where the terms "including / includes," "having / has / with" or variations thereof are used in the detailed description or claims, such terms are intended to be inclusive in a manner similar to the term "comprising."
[0208] The term "about" or "approximately" means within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, for example, limitations of the measurement system. For example, "about" can mean within one or more standard deviations, as practiced in the art. Alternatively, "about" can mean a range of up to 20%, up to 15%, up to 10%, up to 5%, or up to 1% of a given value.
[0209] As used herein, "cell" refers to a biological cell. A cell can be the basic structure, function, or biological unit of a living organism. A cell can be derived from any organism having one or more cells. Some non-limiting examples include: prokaryotic cells, eukaryotic cells, bacterial cells, archaeal cells, cells of unicellular eukaryotic organisms, protozoan cells, cells from plants (e.g., cells from cultivated crops, fruits, vegetables, cereals, soybeans, corn, maize, wheat, seeds, tomatoes, rice, cassava, sugarcane, pumpkin, hay, potatoes, cotton, hemp, tobacco, flowering plants, conifers, gymnosperms, ferns, club mosses, hornworts, liverworts, mosses), algal cells (e.g., Botryococcus braunii, Chlamydomonas reinhardtii, Nannochloropsis gaditana, Chlorella pyrenoidosa, C. agardh, Sargassum patens, C. Agardh, etc.), seaweed (e.g., kelp), fungal cells (e.g., yeast cells, cells from mushrooms), animal cells, cells from invertebrates (e.g., fruit flies, cnidarians, echinoderms, nematodes, etc.), cells from vertebrates (e.g., fish, amphibians, reptiles, birds, mammals), cells from mammals (e.g., pigs, cows, goats, sheep, rodents, rats, mice, non-human primates, humans, etc.), etc. Sometimes, the cell is not derived from a natural organism (e.g., the cell can be synthetically manufactured, sometimes referred to as an artificial cell).
[0210] As used herein, the term "nucleotide" refers to a base-sugar-phosphate combination. Nucleotide can include synthetic nucleotides. Nucleotide can include synthetic nucleotide analogs. Nucleotide can be a monomeric unit of a nucleic acid sequence (e.g., deoxyribonucleic acid (DNA) and ribonucleic acid (RNA)). The term nucleotide can include: ribonucleoside triphosphates, adenosine triphosphate (ATP), uridine triphosphate (UTP), cytosine triphosphate (CTP), guanosine triphosphate (GTP); and deoxyribonucleoside triphosphates, such as dATP, dCTP, dITP, dUTP, dGTP, dTTP or its derivatives. Such derivatives can include, for example, [αS] dATP, 7-deaza-dGTP and 7-deaza-dATP, as well as nucleotide derivatives that confer nuclease resistance to nucleic acid molecules containing them. As used herein, the term nucleotide can refer to dideoxyribonucleoside triphosphates (ddNTP) and its derivatives. Illustrative examples of dideoxyribonucleoside triphosphates can include, but are not limited to, ddATP, ddCTP, ddGTP, ddITP, and ddTTP. Nucleotides can be unlabeled or detectably labeled, such as with a moiety comprising an optically detectable moiety (e.g., a fluorophore). Labeling can also be performed using quantum dots. Detectable labels can include, for example, radioisotopes, fluorescent labels, chemiluminescent labels, bioluminescent labels, and enzyme labels. Fluorescent labels for nucleotides may include, but are not limited to, fluorescein, 5-carboxyfluorescein (FAM), 2'7'-dimethoxy-4'5-dichloro-6-carboxyfluorescein (JOE), rhodamine, 6-carboxyrhodamine (R6G), N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA), 6-carboxy-X-rhodamine (ROX), 4-(4'-dimethylaminophenylazo)benzoic acid (DABCYL), Cascade Blue, Oregon Green, Texas Red, cyanine, and 5-(2'-aminoethyl)aminonaphthalene-1-sulfonic acid (EDANS).Specific examples of fluorescently labeled nucleotides can include: [R6G]dUTP, [TAMRA]dUTP, [R110]dCTP, [R6G]dCTP, [TAMRA]dCTP, [JOE]ddATP, [R6G]ddATP, [FAM]ddCTP, [R110]ddCTP, [TAMRA]ddGTP, [ROX]ddTTP, [dR6G]ddATP, [dR110]ddCTP, [dTAMRA]ddGTP, and [dROX]ddTTP, available from Perkin Elmer, Foster City, Calif.; FluoroLink deoxynucleotides, FluoroLink Cy3-dCTP, FluoroLink Cy5-dCTP, FluoroLink FluorX-dCTP, FluoroLink Cy3-dUTP, and FluoroLink Cy5-dUTP; fluorescein-15-dATP, fluorescein-12-dUTP, tetramethyl-rhodamine-6-dUTP, IR770-9-dATP, fluorescein-12-ddUTP, fluorescein-12-UTP, and fluorescein-15-2′-dATP available from Boehringer Mannheim, Indianapolis, Ind.; and fluorescein-15-dATP available from Molecular Probes, Inc., Eugene, Oreg. Chromosomally labeled nucleotides obtained from Biomarkers, Inc., Eugene, Oreg., BODIPY-FL-14-UTP, BODIPY-FL-4-UTP, BODIPY-TMR-14-UTP, BODIPY-TMR-14-dUTP, BODIPY-TR-14-UTP, BODIPY-TR-14-dUTP, Cascade Blue-7-UTP, Cascade Blue-7-dUTP, Fluorescein-12-UTP, Fluorescein-12-dUTP, Oregon Green 488-5-dUTP, Rhodamine Green-5-UTP, Rhodamine Green-5-dUTP, Tetramethylrhodamine-6-UTP, Tetramethylrhodamine-6-dUTP, Texas Red-5-UTP, Texas Red-5-dUTP, and Texas Red-12-dUTP. Nucleotides can also be labeled or marked by chemical modification. The chemically modified single nucleotide may be a biotin-dNTP.Some non-limiting examples of biotinylated dNTPs can include biotin-dATP (e.g., bio-N6-ddATP, biotin-14-dATP), biotin-dCTP (e.g., biotin-11-dCTP, biotin-14-dCTP), and biotin-dUTP (e.g., biotin-11-dUTP, biotin-16-dUTP, biotin-20-dUTP).
[0211] The terms "polynucleotide," "oligonucleotide," and "nucleic acid" are used interchangeably to refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides or their analogs, in single-stranded, double-stranded, or multi-stranded form. Polynucleotides can be exogenous or endogenous to the cell. Polynucleotides can be present in a cell-free environment. Polynucleotides can be genes or fragments thereof. Polynucleotides can be DNA. Polynucleotides can be RNA. In a polynucleotide, when T is mentioned, T means U (uracil) in RNA and T (thymine) in DNA. Polynucleotides can have any three-dimensional structure and can perform any function. Polynucleotides can include one or more analogs (e.g., altered backbones, sugars, or nucleobases). If present, modifications to the nucleotide structure can be imparted before or after assembly of the polymer. Some non-limiting examples of analogs include: 5-bromouracil, peptide nucleic acids, heterologous nucleic acids, morpholinos, locked nucleic acids, glycerol nucleic acids, threose nucleic acids, dideoxynucleotides, cordycepin, 7-deaza-GTP, fluorophores (e.g., rhodamine or fluorescein linked to a sugar), thiol-containing nucleotides, biotin-linked nucleotides, fluorescent base analogs, CpG islands, methyl-7-guanosine, methylated nucleotides, inosine, thiouridine, pseudouridine, dihydrouridine, quercetin, and wyosine. Non-limiting examples of polynucleotides include coding or non-coding regions of a gene or gene fragment, multiple loci defined by linkage analysis (locus), exons, introns, messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), short interfering RNA (siRNA), short hairpin RNA (shRNA), microRNA (miRNA), ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, cell-free polynucleotides including cell-free DNA (cfDNA) and cell-free RNA (cfRNA), nucleic acid probes and primers. The nucleotide sequence may be interrupted by non-nucleotide components.
[0212] The term "transfection" or "transfected" refers to the introduction of nucleic acids into cells by non-viral or viral-based methods. The nucleic acid molecule can be a gene sequence encoding a complete protein or a functional portion thereof. See, for example, Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 18.1-18.88.
[0213] The terms "peptide," "polypeptide," and "protein" are used interchangeably herein to refer to a polymer of at least two amino acid residues joined by a peptide bond. This term does not indicate the specific length of the polymer, nor is it intended to imply or distinguish whether the peptide is produced using recombinant technology, chemical or enzymatic synthesis, or is naturally occurring. The terms apply to naturally occurring amino acid polymers as well as amino acid polymers comprising at least one modified amino acid. In some cases, the polymer may be interspersed with non-amino acids. The terms encompass amino acid chains of any length, including full-length proteins and proteins with or without secondary or tertiary structures (e.g., domains). The terms also encompass amino acid polymers that have been modified; for example, by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, oxidation, and any other manipulations, such as conjugation with a labeling component. As used herein, the terms "amino acid" and "amino acids" refer to natural and non-natural amino acids, including but not limited to modified amino acids and amino acid analogs. Modified amino acids may include natural and non-natural amino acids that have been chemically modified to include groups or chemical moieties that are not naturally present on amino acids. Amino acid analogs may refer to amino acid derivatives. The term "amino acid" encompasses D-amino acids and L-amino acids.
[0214] As used herein, "non-natural" can refer to nucleic acid or peptide sequences that are not found in natural nucleic acids or proteins. Non-natural can refer to affinity tags. Non-natural can refer to fusions. Non-natural can refer to naturally occurring nucleic acids or peptide sequences that include mutations, insertions, or deletions. The activity (e.g., enzymatic activity, methyltransferase activity, acetyltransferase activity, kinase activity, ubiquitination activity, etc.) that a non-natural sequence can exhibit or encode can also be exhibited by the nucleic acid or peptide sequence fused to the non-natural sequence. Non-natural nucleic acids or peptide sequences can be connected to naturally occurring nucleic acids or peptide sequences (or variants thereof) to produce chimeric nucleic acids or the peptide sequence encoding chimeric nucleic acids or polypeptides through genetic engineering.
[0215] As used herein, the term "promoter" refers to a regulatory DNA region that controls polynucleotide (e.g., gene) transcription or expression and that may be located adjacent to or overlapping a nucleotide or nucleotide region that initiates RNA transcription. A promoter may contain a specific DNA sequence that binds a protein factor (commonly referred to as a transcription factor) that promotes the binding of RNA polymerase to DNA, thereby leading to gene transcription. A "basal promoter," also referred to as a "core promoter," may refer to a promoter containing all the basic essential elements that promote the transcriptional expression of an operably linked polynucleotide. Eukaryotic basal promoters typically (although not necessarily) contain a TATA box and / or a CAAT box.
[0216] As used herein, the term "expression" refers to the process of transcribing a nucleic acid sequence or polynucleotide from a DNA template (e.g., into mRNA or other RNA transcripts) or the subsequent translation of the transcribed mRNA into a peptide, polypeptide, or protein. Transcripts and encoded polypeptides may be collectively referred to as "gene products." If the polynucleotide is derived from genomic DNA, expression may include splicing of the mRNA in eukaryotic cells.
[0217] As used herein, " operably connected ", " operably connected ", " operably connected " or its grammatical equivalent refer to genetic elements, for example the arrangement of promotor, enhancer, polyadenylation sequence etc., wherein the operation of the first genetic element (for example, move or activate) has some influences on the second genetic element.The influence on the second genetic element can be but need not be the type identical with the operation of the first genetic element.For example, if the movement of the first element causes the activation of the second element, then two genetic elements are operably connected.For example, if regulating and controlling element helps to start the transcription of encoding sequence, then the regulating and controlling element that can comprise promotor and / or enhancer sequence is operably connected to the coding region.As long as maintain this functional relationship, there will be insertion residue between regulating and controlling element and the coding region.
[0218] As used herein, "vector" refers to a macromolecule or macromolecular associate that includes or associates with a polynucleotide and can be used to mediate the delivery of the polynucleotide to a cell. Examples of vectors include plasmids, viral vectors, liposomes, and other gene delivery vehicles. Vectors typically include genetic elements (e.g., regulatory elements) that are operably linked to a gene to promote expression of the gene in the target.
[0219] As used herein, "expression cassette" and "nucleic acid cassette" are used interchangeably to refer to a combination of nucleic acid sequences or elements that are expressed together or operably linked for expression. In some cases, an expression cassette refers to a combination of a regulatory element and one or more genes to which it is operably linked for expression.
[0220] A "functional fragment" of a DNA or protein sequence is one that retains a biological activity (functional or structural) substantially similar to that of the full-length DNA or protein sequence. The biological activity of a DNA sequence may be its ability to affect expression in a manner attributed to the full-length sequence.
[0221] The terms "engineered," "synthetic," and "artificial" are used interchangeably herein to refer to an object that has been modified through human intervention. For example, the terms may refer to a non-naturally occurring polynucleotide or polypeptide. An engineered peptide may have, but need not have, low sequence identity (e.g., less than 50% sequence identity, less than 25% sequence identity, less than 10% sequence identity, less than 5% sequence identity, less than 1% sequence identity) to a naturally occurring human protein. For example, the VPR and VP64 domains are synthetic transactivation domains. For example, the VPR and VP64 domains are synthetic transactivation domains. By way of non-limiting example: a nucleic acid can be modified by changing its sequence to a sequence that does not exist in nature; a nucleic acid can be modified by ligating it to a nucleic acid that is not associated with it in nature, such that the ligation product has a function that does not exist in the original nucleic acid; an engineered nucleic acid can be synthesized in vitro using a sequence that does not exist in nature; a protein can be modified by changing its amino acid sequence to a sequence that does not exist in nature; an engineered protein can acquire new functions or properties. An "engineered" system includes at least one engineered component.
[0222] The term "tracrRNA" or "tracr sequence" means trans-activating CRISPR RNA. TracrRNA interacts with CRISPR (cr) RNA to form guide (g) RNA in type II and subtype VB CRISPR-Cas systems. If tracrRNA is engineered, it can have about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 100% sequence identity and / or sequence similarity with a wild-type exemplary tracrRNA sequence (e.g., tracrRNA from Streptococcus pyogenes (S. pyogenes), Staphylococcus aureus (S. aureus)). TracrRNA can refer to a modified form of tracrRNA, which may include nucleotide changes such as deletions, insertions or substitutions, variants, mutations or chimeras. TracrRNA can refer to a nucleic acid that is at least about 60% identical to a wild-type exemplary tracrRNA sequence (e.g., tracrRNA from Streptococcus pyogenes, Staphylococcus aureus, etc.) over a stretch of at least 6 consecutive nucleotides. For example, a tracrRNA sequence can be at least about 60% identical, at least about 65% identical, at least about 70% identical, at least about 75% identical, at least about 80% identical, at least about 85% identical, at least about 90% identical, at least about 95% identical, at least about 98% identical, at least about 99% identical, or 100% identical to a wild-type exemplary tracrRNA sequence (e.g., tracrRNA from Streptococcus pyogenes, Staphylococcus aureus, etc.) over a stretch of at least 6 consecutive nucleotides. Type II tracrRNA sequences can be predicted on genomic sequences by identifying regions that are complementary to partial repeat sequences in adjacent CRISPR arrays.
[0223] As used herein, "guide nucleic acid" or "guide polynucleotide" refers to a nucleic acid that can hybridize with a target nucleic acid and thereby guide the associated nuclease to the target nucleic acid. A guide nucleic acid can be RNA (guide RNA or gRNA). A guide nucleic acid can be DNA. A guide nucleic acid can be a mixture of RNA and DNA. A guide nucleic acid can include crRNA or tracrRNA, or a combination of both. A guide nucleic acid can be engineered. A guide nucleic acid can be programmed to specifically bind to a target nucleic acid. A portion of a target nucleic acid can be complementary to a portion of a guide nucleic acid. The strand of a double-stranded target polynucleotide that is complementary to and hybridizes with a guide nucleic acid can be referred to as a complementary strand. The strand of a double-stranded target polynucleotide that is complementary to a complementary strand and therefore may not be complementary to a guide nucleic acid can be referred to as a non-complementary strand. A guide nucleic acid can include a polynucleotide strand and can be referred to as a "single guide nucleic acid." A guide nucleic acid can include two polynucleotide strands and can be referred to as a "dual guide nucleic acid." Unless otherwise specified, the term "guide nucleic acid" can be inclusive and refer to both single and dual guide nucleic acids. A guide nucleic acid can include a segment that can be referred to as a "nucleic acid targeting segment," "nucleic acid targeting sequence," or "spacer." The nucleic acid-targeting segment may include subsegments, which may be referred to as "protein-binding segments" or "protein-binding sequences" or "Cas protein-binding segments."
[0224] As used herein, the terms "gene editing" and "genome editing" can be used interchangeably. Gene editing or genome editing means changing the nucleic acid sequence of a gene or genome. Genome editing can include, for example, insertions, deletions, and mutations.
[0225] In the context of two or more nucleic acid or polypeptide sequences, the term "sequence identity" or "percent identity" refers to two (e.g., in a pairwise alignment) or more (e.g., in a multiple sequence alignment) sequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence over a local or global comparison window, as measured using a sequence comparison algorithm. Suitable sequence comparison algorithms for polypeptide sequences include, for example, BLASTP using parameters with a word length (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix with gap penalties set to 11 for opening, 1 for expansion, and adjusted using a conditional composition scoring matrix for polypeptide sequences longer than 30 residues; BLASTP using parameters with a word length (W) of 2, an expectation (E) of 1,000,000, and the PAM30 scoring matrix (for sequences of less than 30 residues, the gap penalty is set to 9 to open a gap and to 1 to expand a gap) (these are the parameters of the BLAST suite). BLASTP with default parameters, available at https: / / blast.ncbi.nlm.nih.gov); CLUSTALW with parameters; Smith-Waterman homology search algorithm with the following parameters: matches of 2, mismatches of -1, and gaps of -1; MUSCLE with default parameters; MAFFT with the following parameters: retree of 2 and maxiterations of 1000; Novafold with default parameters; HMMER hmmalign with default parameters.
[0226] As used herein, the term "RuvC_III domain" refers to the third discontinuous segment of the RuvC endonuclease domain (the RuvC nuclease domain comprises three discontinuous segments, RuvC_I, RuvC_II, and RuvC_III). A RuvC domain or its segments can generally be identified by comparing with a recorded domain sequence, with a structural alignment of proteins with annotated domains, or by comparing with a Hidden Markov Model (HMM) constructed based on a recorded domain sequence (e.g., Pfam HMM PF18541 of RuvC_III).
[0227] As used herein, the term "wedge-shaped" (WED) domain refers to a domain that primarily interacts with the repeat:anti-repeat duplex of the sgRNA and PAM duplex (e.g., present in Cas proteins). WED domains can typically be identified by alignment with recorded domain sequences, alignment with proteins with annotated domains, or by comparison with a hidden Markov model (HMM) constructed based on recorded domain sequences.
[0228] As used herein, the term "PAM interaction domain" or "PI domain" refers to a domain that interacts with a protospacer adjacent motif (PAM) outside the seed sequence in the region targeted by the Cas protein. Examples of PAM interaction domains include, but are not limited to, topoisomerase homology (TOPO) domains and C-terminal domains (CTDs) present in Cas proteins. PAM interaction domains or segments thereof can typically be identified by alignment with recorded domain sequences, alignment with proteins having annotated domains, or by comparison with a hidden Markov model (HMM) constructed based on recorded domain sequences.
[0229] As used herein, the term "REC domain" refers to a domain (e.g., present in a Cas protein) comprising at least one of two segments (REC1 or REC2), the two segments being alpha helical domains that are thought to contact guide RNAs. A REC domain or a segment thereof can typically be identified by comparison with a recorded domain sequence, with a structural alignment of proteins with annotated domains, or with a hidden Markov model (HMM) constructed based on a recorded domain sequence (e.g., Pfam PF19501 of domain REC1).
[0230] As used herein, the term "BH domain" refers to a domain that serves as a bridge helix between the NUC and REC lobes of a type II Cas enzyme (e.g., present in a Cas protein). A BH domain or a segment thereof can typically be identified by alignment with a recorded domain sequence, alignment with a structure of a protein with annotated domains, or by comparison with a hidden Markov model (HMM) constructed based on a recorded domain sequence (e.g., Pfam PF16593 for domain BH).
[0231] As used herein, the term "HNH domain" refers to an endonuclease domain having characteristic histidine and asparagine residues. HNH domains can typically be identified by comparison with recorded domain sequence alignments, with structural alignments of proteins with annotated domains, or by comparison with a hidden Markov model (HMM) constructed based on recorded domain sequences (e.g., the Pfam HMM PF01844 for the domain HNH).
[0232] The present disclosure includes variants of any enzyme in the enzymes with one or more conservative amino acid substitutions described herein. Such conservative substitutions can be carried out in the amino acid sequence of a polypeptide without destroying the three-dimensional structure or function of the polypeptide. Conservative substitutions can be completed by replacing each other with amino acids having similar hydrophobicity, polarity and R chain length. Additionally or alternatively, by comparing the alignment sequences of homologous proteins from different species, conservative substitutions can be identified by positioning the amino acid residues that mutate between species (e.g., non-conservative residues) without changing the basic function of the encoded protein. Such conservatively substituted variants can include variants with at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% homogeneity with any system in the systems described herein. In some embodiments, such conservatively substituted variants are functional variants. Such functional variants can encompass sequences with substitutions so that the activity of the key active site residues of the endonuclease is not destroyed. In some embodiments, the functional variants of any system in the systems described herein lack substitutions of at least one of the conserved residues or functional residues described herein. In some embodiments, the functional variants of any system in the systems described herein lack substitutions of all of the conserved residues or functional residues described herein.
[0233] Conservative substitution tables providing functionally similar amino acids are available from various references (see, for example, Creighton, Proteins: Structures and Molecular Properties (WH Freeman & Co.; 2nd ed. (December 1993)). The following eight groups each contain amino acids that are conservative substitutions for one another:
[0234] 1) Alanine (A), glycine (G);
[0235] 2) Aspartic acid (D), glutamic acid (E);
[0236] 3) Asparagine (N), glutamine (Q);
[0237] 4) Arginine (R), Lysine (K);
[0238] 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V);
[0239] 6) Phenylalanine (F), tyrosine (Y), tryptophan (W);
[0240] 7) Serine (S), Threonine (T); and
[0241] 8) Cysteine (C), methionine (M).
[0242] Overview
[0243] The discovery of new Cas enzymes with unique functions and structures may offer the potential to further disrupt deoxyribonucleic acid (DNA) editing technologies, thereby improving speed, specificity, functionality, and ease of use. Relative to the predicted prevalence of clustered regularly interspaced short palindromic repeat (CRISPR) systems in microorganisms and the sheer diversity of microbial species, there are relatively few functionally characterized CRISPR / Cas enzymes in the literature. This is partly because a large number of microbial species may not be easily cultured under laboratory conditions. Metagenomic sequencing of natural environmental niches representing a large number of microbial species may offer the potential to significantly increase the number of new CRISPR / Cas systems documented and accelerate the discovery of new oligonucleotide editing functions. A recent example of the fruitfulness of this approach was demonstrated by the discovery of the CasX / CasY CRISPR system in 2016 through metagenomic analysis of natural microbial communities.
[0244] The CRISPR / Cas system is an RNA-guided nuclease complex that has been described as acting as an adaptive immune system in microorganisms. In its natural environment, the CRISPR / Cas system occurs in a CRISPR (clustered regularly interspaced short palindromic repeats) operator or locus, and the system generally comprises two parts: (i) an array of short repeat sequences (30-40 bp) separated by equally short spacer sequences, which encode RNA-based targeting elements; and (ii) an ORF encoding a Cas sequence encoding a nuclease polypeptide guided by RNA-based targeting elements and auxiliary proteins / enzymes. Efficient nuclease targeting of a specific target nucleic acid sequence may involve the following two: (i) complementary hybridization between the first 6-8 nucleic acids of the target (target seed) and the crRNA guide; and (ii) the presence of a protospacer adjacent motif (PAM) sequence within the defined vicinity of the target seed (PAM is typically a sequence not commonly represented in the host genome). Depending on the exact function and organization of the system, CRISPR-Cas systems are generally divided into 2 categories, 5 types, and 16 subtypes based on shared functional properties and evolutionary similarities.
[0245] Class 1 CRISPR-Cas systems have large multi-subunit effector complexes and include types I, III, and IV.
[0246] I type CRISPR-Cas system is considered to have medium complexity in terms of components.In I type CRISPR-Cas system, the array of RNA targeting element is transcribed into long precursor crRNA (crRNA precursor), and the crRNA precursor is processed to discharge short mature crRNA at repeat element place, when followed by the suitable short consensus sequence of being referred to as protospacer adjacent motif (PAM), the short mature crRNA guides nuclease complex to nucleic acid target.This treatment is carried out by the endoribonuclease subunit (Cas6) of the large endonuclease complex of being referred to as cascade, and the endonuclease complex also includes the nuclease (Cas3) protein component of the nuclease complex guided by crRNA.Cas I nuclease mainly serves as DNA nuclease.
[0247] Type III CRISPR systems may be characterized by the presence of a central nuclease called Cas10 and a repeat-associated mysterious protein (RAMP) that includes Csm or Cmr protein subunits. As in type I systems, mature crRNA is processed by a crRNA precursor using a Cas6-like enzyme. Unlike type I and type II systems, type III systems appear to target and cleave DNA-RNA duplexes (such as the DNA chain used as a template for RNA polymerase).
[0248] Type IV CRISPR-Cas systems have an effector complex that includes a highly reduced large subunit nuclease (csf1), two genes for the Cas5 (csf3) and Cas7 (csf2) groups of RAMP proteins, and in some cases, genes for predicted small subunits; such systems are typically found on endogenous plasmids.
[0249] Class 2 CRISPR-Cas systems typically have single-polypeptide multidomain nuclease effectors and include types II, V, and VI.
[0250] Type II CRISPR-Cas systems are considered to be the simplest in terms of components. In type II CRISPR-Cas systems, the CRISPR array is processed into mature crRNA without the presence of special nuclease subunits, but requires a small trans-encoded crRNA (tracrRNA), whose region is complementary to the array repeat sequence; tracrRNA interacts with its corresponding effector nuclease (e.g., Cas9) and repeat sequence to form a precursor dsRNA structure, which is cut by endogenous RNase III, thereby producing a mature effector enzyme loaded with tracrRNA and crRNA. Cas II nucleases are recorded as DNA nucleases. Type 2 effectors typically exhibit a structure including a RuvC-like nuclease domain, which adopts an RNase H fold, wherein an unrelated HNH nuclease domain is inserted into the fold of the RuvC-like nuclease domain. RuvC-like domains are responsible for the cutting of target (e.g., crRNA complementary) DNA chains, while HNH domains are responsible for the cutting of displaced DNA chains.
[0251] The V-type CRISPR-Cas system is characterized by a nuclease effector (e.g., Cas12) structure similar to the structure of the type II effector including a RuvC-like domain. Similar to type II, most (but not all) V-type CRISPR systems use tracrRNA to process the crRNA precursor into mature crRNA; however, unlike the type II system that requires RNase III to cut the crRNA precursor into multiple crRNAs, the V-type system is able to use the effector nuclease itself to cut the crRNA precursor. Like the type II CRISPR-Cas system, the V-type CRISPR-Cas system is again recorded as a DNA nuclease. Unlike the type II CRISPR-Cas system, some V-type enzymes (e.g., Cas12a) appear to have powerful single-stranded nonspecific deoxyribonuclease activity activated by the first crRNA-directed cutting of the double-stranded target sequence.
[0252] Type VI CRISPR-Cas systems have RNA-guided RNA endonucleases. The single polypeptide effector of a Type VI system (e.g., Cas13) includes two HEPN ribonuclease domains, rather than a RuvC-like domain. Unlike Type II and Type V systems, Type VI systems do not seem to require tracrRNA in some embodiments to process the crRNA precursor into crRNA. However, similar to Type V systems, some Type VI systems (e.g., C2C2) appear to have powerful single-stranded nonspecific nuclease (ribonuclease) activity activated by the first crRNA-directed cutting of the target RNA.
[0253] Class 2 CRISPR-Cas has been most widely used in engineering and development as a designer nuclease / genome editing application due to its simpler architecture.
[0254] One of the early adaptations of this system for in vitro use involved (i) recombinantly expressed, purified full-length Cas9 (e.g., class 2, type II Cas enzyme) isolated from Streptococcus pyogenes SF370; (ii) purified mature, approximately 42 nt crRNA carrying an approximately 20 nt 5' sequence complementary to the target DNA sequence desired to be cleaved, followed by a 3' tracr-binding sequence (the entire crRNA was in vitro transcribed from a synthetic DNA template carrying a T7 promoter sequence); (iii) purified tracrRNA in vitro transcribed from a synthetic DNA template carrying a T7 promoter sequence; and (iv) MgCl2. 2+ A later improved engineered system involves joining the crRNA of (ii) to the 5' end of (iii) via a linker (e.g., GAAA) to form a single fused synthetic guide RNA (sgRNA) that can itself guide Cas9 to the target.
[0255] Such an engineered system can be adapted for mammalian cells by providing a DNA vector encoding: (i) an ORF encoding a codon-optimized Cas9 (e.g., a Class 2 type II Cas enzyme) under a suitable mammalian promoter with a C-terminal nuclear localization sequence (e.g., SV40 NLS) and a suitable polyadenylation signal (e.g., TK pA signal); and (ii) an ORF encoding an sgRNA (having a 5' sequence beginning with G followed by a 20 nt complementary targeting nucleic acid sequence joined to a 3' tracr binding sequence, a linker, and a tracrRNA sequence) under a suitable polymerase III promoter (e.g., U6 promoter).
[0256] Engineered endonucleases
[0257] In certain embodiments, engineered endonucleases are described herein. In certain embodiments, the engineered endonucleases are chimeras of two or more endonucleases. In certain embodiments, the engineered endonucleases are fusions of two or more endonucleases.
[0258] In certain embodiments, engineered endonucleases include one or more fragments or domains of nucleases, such as nucleic acid-guided nucleases. In certain embodiments, engineered endonucleases include one or more fragments or domains of nucleases from orthologs of organisms, genera, species, or other phylogenetic groups described herein. In certain embodiments, engineered endonucleases include one or more fragments or domains of nucleases from orthologs of nucleases from different species.
[0259] In some embodiments, the engineered endonuclease comprises one or more fragments or domains from at least two different nucleases. In some embodiments, the engineered endonuclease comprises one or more fragments or domains from at least 2, 3, 4, 5, 6, 7, 8, 9, 10 or more different nucleases. In some embodiments, the engineered endonuclease comprises one or more fragments or domains from at least 2, 3, 4, 5, 6, 7, 8, 9, 10 or more nucleases from different species. In some embodiments, the engineered endonuclease comprises 2 fragments or domains, each fragment or domain is from a different nuclease. In some embodiments, the engineered endonuclease comprises 3 fragments or domains, each fragment or domain is from a different nuclease. In some embodiments, the engineered endonuclease comprises 4 fragments or domains, each fragment or domain is from a different nuclease. In some embodiments, the engineered endonuclease comprises 5 fragments or domains, each fragment or domain is from a different nuclease. In some embodiments, the engineered endonuclease comprises 3 fragments or domains, at least one of which is from a different nuclease. In some embodiments, the engineered endonuclease comprises 4 fragments or domains, wherein at least one fragment or domain is from a different nuclease. In some embodiments, the engineered endonuclease comprises 5 fragments or domains, wherein at least one fragment or domain is from a different nuclease.
[0260] In some embodiments, the engineered endonuclease is functional in a prokaryotic or eukaryotic cell for in vitro, in vivo, or ex vivo applications.
[0261] In some embodiments, the endonuclease is derived from an uncultured microorganism. In some embodiments, the engineered endonuclease is not a Cas9 endonuclease, a Cas14 endonuclease, a Cas12a endonuclease, a Cas12b endonuclease, a Cas 12c endonuclease, a Cas12d endonuclease, a Cas12e endonuclease, a Cas13a endonuclease, a Cas13b endonuclease, a Cas13c endonuclease, or a Cas13d endonuclease. In some embodiments, the engineered endonuclease has less than 86% identity to a SpyCas9 endonuclease.
[0262] In some embodiments, the connection between fragments or domains from different nucleases or species occurs in multiple unstructured regions. Unstructured regions in polynucleotides include, for example, regions without predicted secondary structural elements (such as α helices or β strands). Unstructured regions can include, for example, regions exposed within the protein structure, loop regions, or regions that are not conserved within various protein orthologs as predicted by sequence or structural comparisons.
[0263] In certain embodiments, described herein are engineered endonucleases (e.g., chimeric endonucleases or fusion endonucleases) comprising an N-terminal portion comprising a sequence having at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 696; and a C-terminal portion comprising a sequence having at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 696; NO:697-721 have a sequence having at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity. In some embodiments, the engineered endonuclease comprises an N-terminal portion comprising a sequence having at least about 70% identity to SEQ ID NO:696 and a C-terminal portion comprising a sequence having at least about 70% identity to any one of SEQ ID NO:697-721. In some embodiments, the engineered endonuclease comprises an N-terminal portion comprising a sequence having at least about 75% identity to SEQ ID NO: 696 and a C-terminal portion comprising a sequence having at least about 75% identity to any one of SEQ ID NOs: 697-721. In some embodiments, the engineered endonuclease comprises an N-terminal portion comprising a sequence having at least about 80% identity to SEQ ID NO: 696 and a C-terminal portion comprising a sequence having at least about 80% identity to any one of SEQ ID NOs: 697-721. In some embodiments, the engineered endonuclease comprises an N-terminal portion comprising a sequence having at least about 85% identity to SEQ ID NO: 696 and a C-terminal portion comprising a sequence having at least about 85% identity to any one of SEQ ID NOs: 697-721.In some embodiments, the engineered endonuclease comprises an N-terminal portion comprising a sequence at least about 90% identical to SEQ ID NO: 696 and a C-terminal portion comprising a sequence at least about 90% identical to any one of SEQ ID NOs: 697-721. In some embodiments, the engineered endonuclease comprises an N-terminal portion comprising a sequence at least about 95% identical to SEQ ID NO: 696 and a C-terminal portion comprising a sequence at least about 95% identical to any one of SEQ ID NOs: 697-721. In some embodiments, the engineered endonuclease comprises an N-terminal portion comprising a sequence at least about 96% identical to SEQ ID NO: 696 and a C-terminal portion comprising a sequence at least about 96% identical to any one of SEQ ID NOs: 697-721. In some embodiments, the engineered endonuclease comprises an N-terminal portion comprising a sequence having at least about 97% identity to SEQ ID NO: 696 and a C-terminal portion comprising a sequence having at least about 97% identity to any one of SEQ ID NOs: 697-721. In some embodiments, the engineered endonuclease comprises an N-terminal portion comprising a sequence having at least about 98% identity to SEQ ID NO: 696 and a C-terminal portion comprising a sequence having at least about 98% identity to any one of SEQ ID NOs: 697-721. In some embodiments, the engineered endonuclease comprises an N-terminal portion comprising a sequence having at least about 99% identity to SEQ ID NO: 696 and a C-terminal portion comprising a sequence having at least about 99% identity to any one of SEQ ID NOs: 697-721. In some embodiments, the engineered nuclease comprises an N-terminal portion comprising a sequence that is 100% identical to SEQ ID NO: 696 and a C-terminal portion comprising a sequence that is 100% identical to any one of SEQ ID NOs: 697-721.
[0264] In certain embodiments, described herein are engineered endonucleases (e.g., chimeric endonucleases or fusion endonucleases) comprising an N-terminal portion comprising a RuvC, REC, or HNH domain of a Cas endonuclease and having at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 696; and a C-terminal portion comprising a WED, TOPO, or CTD domain of a Cas endonuclease and having at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 696. Any of NOs:697-721 has at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity.
[0265] In certain embodiments, the N-terminal portion of the engineered endonuclease includes a RuvC domain, a REC domain, an HNH domain, a BH domain, or a combination thereof. In certain embodiments, the C-terminal portion of the engineered endonuclease includes a WED domain, a TOPO domain, a CTD domain, a PAM interaction domain, or a combination thereof. In certain embodiments, the N-terminal portion of the engineered endonuclease includes a RuvC, REC, and HNH domain. In certain embodiments, the N-terminal portion of the engineered endonuclease includes a RuvC and HNH domain. In certain embodiments, the N-terminal portion of the engineered endonuclease further includes a RuvC, REC, HNH, RuvC-I, BH, and RuvC-II domain. In certain embodiments, the C-terminal portion of the engineered endonuclease includes a WED, TOPO, and CTD domain. In certain embodiments, the C-terminal portion of the engineered endonuclease includes a PAM interaction domain.
[0266] In some embodiments, the N-terminal portion of the engineered endonuclease and the C-terminal portion of the engineered endonuclease do not naturally occur together in the same reading frame. In some embodiments, the N-terminal portion of the engineered endonuclease and the C-terminal portion of the engineered endonuclease are derived from different organisms.
[0267] In certain embodiments, the N-terminal portion of the engineered endonuclease and the C-terminal portion of the engineered endonuclease are directly fused. In certain embodiments, the N-terminal portion of the engineered endonuclease and the C-terminal portion of the engineered endonuclease are joined by a joint. In certain embodiments, the joint is a joint rich in glycine and / or serine, a large protein domain, a long helical structure or a short helical structure. In certain embodiments, the joint is (G4S)n, and wherein n is an integer from 1 to 20. In certain embodiments, the joint is GGGGS (SEQ ID NO: 2864). In certain embodiments, the joint includes a sequence selected from the group consisting of: (GS)n, (G2S)n, (G3S)n, (G4S)n and (G)n, and wherein n is an integer from 1 to 20. In certain embodiments, one or more joints include a sequence selected from the group consisting of: (GGSGGD)n or (GGSGGE)n, and wherein n is an integer from 1 to 6. In some embodiments, the one or more linkers comprise a sequence selected from the group consisting of: (GGGSGGG)n, (GGGSGSGGGGS)n, and (GGGGGPGGGGP)n, and wherein n is an integer from 1 to 3. In some embodiments, the one or more linkers comprise a sequence selected from the group consisting of: (GX)n, (GGX)n, (GGGX)n, (GGGGX)n, and (GzX)n, wherein z is between 1 and 20, and wherein n is at least 8. In some embodiments, X is serine, aspartic acid, glutamic acid, threonine, or proline.
[0268] In some embodiments, the engineered endonuclease (e.g., a chimeric endonuclease or a fusion endonuclease) comprises a sequence having at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862. In some embodiments, the engineered endonuclease comprises a sequence having at least about 70% identity to any one of SEQ ID NOs: 1-27 and 771-862. In some embodiments, the engineered endonuclease comprises a sequence having at least about 75% identity to any one of SEQ ID NOs: 1-27 and 771-862. In some embodiments, the engineered endonuclease comprises a sequence having at least about 80% identity to any one of SEQ ID NOs: 1-27 and 771-862. In some embodiments, the engineered endonuclease comprises a sequence having at least about 85% identity to any one of SEQ ID NOs: 1-27 and 771-862. In some embodiments, the engineered endonuclease comprises a sequence having at least about 90% identity to any one of SEQ ID NOs: 1-27 and 771-862. In some embodiments, the engineered endonuclease comprises a sequence having at least about 95% identity to any one of SEQ ID NOs: 1-27 and 771-862. In some embodiments, the engineered endonuclease comprises a sequence having at least about 96% identity to any one of SEQ ID NOs: 1-27 and 771-862. In some embodiments, the engineered endonuclease comprises a sequence that is at least about 97% identical to any one of SEQ ID NOs: 1-27 and 771-862. In some embodiments, the engineered endonuclease comprises a sequence that is at least about 98% identical to any one of SEQ ID NOs: 1-27 and 771-862. In some embodiments, the engineered endonuclease comprises a sequence that is at least about 99% identical to any one of SEQ ID NOs: 1-27 and 771-862. In some embodiments, the engineered endonuclease comprises a sequence that is 100% identical to any one of SEQ ID NOs: 1-27 and 771-862.
[0269] In some embodiments, the engineered endonucleases described herein have natural PAM specificity (see Figure 1BIn some embodiments, the present disclosure provides for the realization of PAM specificity through protein engineering. In some embodiments, the realization of PAM specificity can be achieved by domain exchange of RNA-guided CRISPR-associated nucleases (see Figure 2 In some embodiments, there is an optimal breakpoint during domain exchange and recombination. In some embodiments, the optimal breakpoint is guided by alignment of multiple sequences as described herein (see Figure 3A ).
[0270] In some embodiments, the engineered endonuclease is configured to bind to a PAM that is not nnRGGnT. In some embodiments, the engineered endonuclease is configured to bind to a PAM in Table 1A. In some embodiments, the engineered endonuclease is configured to bind to a PAM comprising the sequence of any of the following: nnRGGnT, nnnmtY, nnnCCCy, nnraww, nnRnYAY, nnnctC, nnRGGTY, nnRGGTY, nnnctC, nnRnYAY, nnnMWTY, nnrRTwy, nnRRTWY, nyrnwYY, nnrCyY, nnncMMc, nnrnYCC, nnncMMc, nnrRnCm, nnnYCMw, nnnmCmC, nnrnynnn, nnnmCm, nnRnYCYr, nnRAYAC, nnnmCm, nnnRMYT, nnTY In some embodiments, the engineered endonuclease is configured to bind to a PAM by recognizing a PAM sequence. In some embodiments, the engineered endonuclease recognizes and binds to a PAM sequence.
[0271] Table 1A: PAM sequences
[0272]
[0273]
[0274]
[0275] In some embodiments, the engineered endonuclease (e.g., a chimeric endonuclease or a fusion endonuclease) comprises a sequence having at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOs: 109-110 and 2842-2854. In some embodiments, the engineered endonuclease comprises a sequence having at least about 70% identity to any one of SEQ ID NOs: 109-110 and 2842-2854. In some embodiments, the engineered endonuclease comprises a sequence having at least about 75% identity to any one of SEQ ID NOs: 109-110 and 2842-2854. In some embodiments, the engineered endonuclease comprises a sequence having at least about 80% identity to any one of SEQ ID NOs: 109-110 and 2842-2854. In some embodiments, the engineered endonuclease comprises a sequence having at least about 85% identity to any one of SEQ ID NOs: 109-110 and 2842-2854. In some embodiments, the engineered endonuclease comprises a sequence having at least about 90% identity to any one of SEQ ID NOs: 109-110 and 2842-2854. In some embodiments, the engineered endonuclease comprises a sequence having at least about 95% identity to any one of SEQ ID NOs: 109-110 and 2842-2854. In some embodiments, the engineered endonuclease comprises a sequence that is at least about 96% identical to any one of SEQ ID NOs: 109-110 and 2842-2854. In some embodiments, the engineered endonuclease comprises a sequence that is at least about 97% identical to any one of SEQ ID NOs: 109-110 and 2842-2854. In some embodiments, the engineered endonuclease comprises a sequence that is at least about 98% identical to any one of SEQ ID NOs: 109-110 and 2842-2854. In some embodiments, the engineered endonuclease comprises a sequence that is at least about 99% identical to any one of SEQ ID NOs: 109-110 and 2842-2854. In some embodiments, the engineered endonuclease comprises a sequence that is 100% identical to any one of SEQ ID NOs: 109-110 and 2842-2854.
[0276] In some embodiments, the engineered endonuclease is configured to bind to a PAM that is not nnRGGnT. In some embodiments, the engineered endonuclease is configured to bind to a PAM in Table 1A. In some embodiments, the engineered endonuclease is configured to bind to a PAM comprising any of the following: TTTn, TYYn, TTTn, nYTn, TTYn, nTTn, nYYn, and nYYn. In some embodiments, the engineered endonuclease is configured to bind to a PAM by recognizing a PAM sequence. In some embodiments, the engineered endonuclease recognizes and binds to a PAM sequence.
[0277] Guide polynucleotides
[0278] In certain embodiments, disclosed herein are endonuclease systems comprising: (a) an engineered nuclease disclosed herein; and (b) a guide polynucleotide, e.g., a guide RNA (gRNA), a single gRNA, or a dual guide RNA. In the polynucleotide, when T is mentioned, T refers to U (uracil) in RNA and T (thymine) in DNA.
[0279] In some embodiments, the engineered guide polynucleotide is configured to form a complex with an engineered endonuclease. In some cases, the engineered guide polynucleotide includes a spacer sequence. In some cases, the spacer sequence is configured to hybridize with a target nucleic acid sequence. In some cases, the endonuclease is configured to bind to a protospacer adjacent motif (PAM) sequence.
[0280] In some embodiments, the guide polynucleotide (e.g., gRNA) targets a gene or locus in a cell. In some embodiments, the guide polynucleotide targets a gene or locus in a mammalian cell. In some embodiments, the mammalian cell is a porcine, bovine, goat, sheep, rodent, rat, mouse, non-human primate, or human cell. In some embodiments, the target gene or locus is albumin, TRAC, B2M, TRBC1, TRBC2, ANGPTL3, PCSK9, VCP R155, AAVS1, GPR146, APOA1, or HAO1.
[0281] In some embodiments, the target gene is albumin. In some embodiments, the guide polynucleotide is encoded by any one of SEQ ID NOs: 67-86, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 67-86. In some embodiments, the guide polynucleotide comprises a sequence comprising at least about 46-80 contiguous nucleotides that is at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to any one of SEQ ID NOs: 67-86. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 80% identical to any one of SEQ ID NOs: 67-86. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 85% identical to any one of SEQ ID NOs: 67-86. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 90% identical to any one of SEQ ID NOs: 67-86. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 95% identical to any one of SEQ ID NOs: 67-86. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 96% identical to any one of SEQ ID NOs: 67-86. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 97% identical to any one of SEQ ID NOs: 67-86. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 98% identical to any one of SEQ ID NOs: 67-86. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 99% identical to any one of SEQ ID NOs: 67-86. In some embodiments, the guide polynucleotide is encoded by a sequence that is 100% identical to any one of SEQ ID NOs: 67-86.
[0282] In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to the target nucleic acid sequence within the albumin gene or within an intron of an endogenous gene. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to any one of SEQ ID NOs: 67-86 or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 67-86. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to a sequence having at least about 80% identity to any one of SEQ ID NOs: 67-86. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to a sequence having at least about 85% identity to any one of SEQ ID NOs: 67-86. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to a sequence having at least about 90% identity to any one of SEQ ID NOs: 67-86. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to a sequence having at least about 95% identity to any one of SEQ ID NOs: 67-86. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 96% identical to any one of SEQ ID NOs: 67-86. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 97% identical to any one of SEQ ID NOs: 67-86. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 98% identical to any one of SEQ ID NOs: 67-86. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 99% identical to any one of SEQ ID NOs: 67-86. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is 100% identical to any one of SEQ ID NOs: 67-86.
[0283] In some embodiments, the target gene is TRAC. In some embodiments, the guide polynucleotide is encoded by any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617. In some embodiments, the guide polynucleotide comprises a sequence comprising at least about 46-80 contiguous nucleotides that is at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 80% identical to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 85% identical to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 90% identical to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 95% identical to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617.In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 96% identical to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 97% identical to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 98% identical to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 99% identical to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617. In some embodiments, the guide polynucleotide is encoded by a sequence that is 100% identical to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617.
[0284] In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to the target nucleic acid sequence within the TRAC gene or within an intron of an endogenous gene. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence having at least about 80% identity to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence having at least about 85% identity to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 90% identical to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 95% identical to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence having at least about 96% identity to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence having at least about 97% identity to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617.In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 98% identical to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 99% identical to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is 100% identical to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617.
[0285] In some embodiments, the guide polynucleotide hybridizes or targets a sequence within the TRAC gene or within an intron of an endogenous gene. In some embodiments, the guide polynucleotide hybridizes or targets a sequence according to any one of SEQ ID NOs: 139-158, 925-927, 992-1011, 1184-1279, 1321-1361, 2486-2581, and 2618-2653, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 139-158, 925-927, 992-1011, 1184-1279, 1321-1361, 2486-2581, and 2618-2653. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 80% identical to any one of SEQ ID NOs: 139-158, 925-927, 992-1011, 1184-1279, 1321-1361, 2486-2581, and 2618-2653. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 85% identical to any one of SEQ ID NOs: 139-158, 925-927, 992-1011, 1184-1279, 1321-1361, 2486-2581, and 2618-2653. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 90% identical to any one of SEQ ID NOs: 139-158, 925-927, 992-1011, 1184-1279, 1321-1361, 2486-2581, and 2618-2653. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 95% identical to any one of SEQ ID NOs: 139-158, 925-927, 992-1011, 1184-1279, 1321-1361, 2486-2581, and 2618-2653. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 96% identical to any one of SEQ ID NOs: 139-158, 925-927, 992-1011, 1184-1279, 1321-1361, 2486-2581, and 2618-2653. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 97% identical to any one of SEQ ID NOs: 139-158, 925-927, 992-1011, 1184-1279, 1321-1361, 2486-2581, and 2618-2653.In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 98% identical to any one of SEQ ID NOs: 139-158, 925-927, 992-1011, 1184-1279, 1321-1361, 2486-2581, and 2618-2653. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 99% identical to any one of SEQ ID NOs: 139-158, 925-927, 992-1011, 1184-1279, 1321-1361, 2486-2581, and 2618-2653. In some embodiments, the guide polynucleotide hybridizes or targets a sequence with 100% identity to any one of SEQ ID NOs: 139-158, 925-927, 992-1011, 1184-1279, 1321-1361, 2486-2581, and 2618-2653.
[0286] In some embodiments, the target gene is B2M. In some embodiments, the guide polynucleotide is encoded by any one of SEQ ID NOs: 159-184, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 159-184. In some embodiments, the guide polynucleotide comprises a sequence comprising at least about 46-80 contiguous nucleotides that is at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to any one of SEQ ID NOs: 159-184. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 80% identical to any one of SEQ ID NOs: 159-184. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 85% identical to any one of SEQ ID NOs: 159-184. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 90% identical to any one of SEQ ID NOs: 159-184. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 95% identical to any one of SEQ ID NOs: 159-184. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 96% identical to any one of SEQ ID NOs: 159-184. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 97% identical to any one of SEQ ID NOs: 159-184. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 98% identical to any one of SEQ ID NOs: 159-184. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 99% identical to any one of SEQ ID NOs: 159-184. In some embodiments, the guide polynucleotide is encoded by a sequence that is 100% identical to any one of SEQ ID NOs: 159-184.
[0287] In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to the target nucleic acid sequence within the B2M gene or within an intron of an endogenous gene. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to any one of SEQ ID NOs: 159-184 or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 159-184. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to a sequence having at least about 80% identity to any one of SEQ ID NOs: 159-184. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to a sequence having at least about 85% identity to any one of SEQ ID NOs: 159-184. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to a sequence having at least about 90% identity to any one of SEQ ID NOs: 159-184. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 95% identical to any one of SEQ ID NOs: 159-184. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 96% identical to any one of SEQ ID NOs: 159-184. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 97% identical to any one of SEQ ID NOs: 159-184. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 98% identical to any one of SEQ ID NOs: 159-184. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 99% identical to any one of SEQ ID NOs: 159-184. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is 100% identical to any one of SEQ ID NOs: 159-184.
[0288] In some embodiments, the guide polynucleotide hybridizes or targets a sequence within the B2M gene or within an intron of an endogenous gene. In some embodiments, the guide polynucleotide hybridizes or targets a sequence according to any one of SEQ ID NOs: 185-210, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 185-210. In some embodiments, the guide polynucleotide hybridizes or targets a sequence having at least about 80% identity to any one of SEQ ID NOs: 185-210. In some embodiments, the guide polynucleotide hybridizes or targets a sequence having at least about 85% identity to any one of SEQ ID NOs: 185-210. In some embodiments, the guide polynucleotide hybridizes or targets a sequence having at least about 90% identity to any one of SEQ ID NOs: 185-210. In some embodiments, the guide polynucleotide hybridizes or targets a sequence having at least about 95% identity to any one of SEQ ID NOs: 185-210. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 96% identical to any one of SEQ ID NOs: 185-210. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 97% identical to any one of SEQ ID NOs: 185-210. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 98% identical to any one of SEQ ID NOs: 185-210. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 99% identical to any one of SEQ ID NOs: 185-210. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is 100% identical to any one of SEQ ID NOs: 185-210.
[0289] In some embodiments, the target gene is TRBC1. In some embodiments, the guide polynucleotide is encoded by any one of SEQ ID NOs: 211-251, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 211-251. In some embodiments, the guide polynucleotide comprises a sequence comprising at least about 46-80 contiguous nucleotides that is at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to any one of SEQ ID NOs: 211-251. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 80% identical to any one of SEQ ID NOs: 211-251. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 85% identical to any one of SEQ ID NOs: 211-251. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 90% identical to any one of SEQ ID NOs: 211-251. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 95% identical to any one of SEQ ID NOs: 211-251. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 96% identical to any one of SEQ ID NOs: 211-251. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 97% identical to any one of SEQ ID NOs: 211-251. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 98% identical to any one of SEQ ID NOs: 211-251. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 99% identical to any one of SEQ ID NOs: 211-251. In some embodiments, the guide polynucleotide is encoded by a sequence that is 100% identical to any one of SEQ ID NOs: 211-251.
[0290] In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to the target nucleic acid sequence within the TRBC1 gene or within an intron of an endogenous gene. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to any one of SEQ ID NOs: 211-251 or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 211-251. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to a sequence having at least about 80% identity to any one of SEQ ID NOs: 211-251. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to a sequence having at least about 85% identity to any one of SEQ ID NOs: 211-251. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to a sequence having at least about 90% identity to any one of SEQ ID NOs: 211-251. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 95% identical to any one of SEQ ID NOs: 211-251. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 96% identical to any one of SEQ ID NOs: 211-251. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 97% identical to any one of SEQ ID NOs: 211-251. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 98% identical to any one of SEQ ID NOs: 211-251. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 99% identical to any one of SEQ ID NOs: 211-251. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is 100% identical to any one of SEQ ID NOs: 211-251.
[0291] In some embodiments, the guide polynucleotide hybridizes or targets a sequence within the TRBC1 gene or within an intron of an endogenous gene. In some embodiments, the guide polynucleotide hybridizes or targets a sequence according to any one of SEQ ID NOs: 252-292 or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 252-292. In some embodiments, the guide polynucleotide hybridizes or targets a sequence having at least about 80% identity to any one of SEQ ID NOs: 252-292. In some embodiments, the guide polynucleotide hybridizes or targets a sequence having at least about 85% identity to any one of SEQ ID NOs: 252-292. In some embodiments, the guide polynucleotide hybridizes or targets a sequence having at least about 90% identity to any one of SEQ ID NOs: 252-292. In some embodiments, the guide polynucleotide hybridizes or targets a sequence having at least about 95% identity to any one of SEQ ID NOs: 252-292. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 96% identical to any one of SEQ ID NOs: 252-292. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 97% identical to any one of SEQ ID NOs: 252-292. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 98% identical to any one of SEQ ID NOs: 252-292. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 99% identical to any one of SEQ ID NOs: 252-292. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is 100% identical to any one of SEQ ID NOs: 252-292.
[0292] In some embodiments, the target gene is TRBC2. In some embodiments, the guide polynucleotide is encoded by any one of SEQ ID NOs: 293-337, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 293-337. In some embodiments, the guide polynucleotide comprises a sequence comprising at least about 46-80 contiguous nucleotides that is at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to any one of SEQ ID NOs: 293-337. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 80% identical to any one of SEQ ID NOs: 293-337. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 85% identical to any one of SEQ ID NOs: 293-337. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 90% identical to any one of SEQ ID NOs: 293-337. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 95% identical to any one of SEQ ID NOs: 293-337. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 96% identical to any one of SEQ ID NOs: 293-337. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 97% identical to any one of SEQ ID NOs: 293-337. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 98% identical to any one of SEQ ID NOs: 293-337. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 99% identical to any one of SEQ ID NOs: 293-337. In some embodiments, the guide polynucleotide is encoded by a sequence that is 100% identical to any one of SEQ ID NOs: 293-337.
[0293] In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to the target nucleic acid sequence within the TRBC2 gene or within an intron of an endogenous gene. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to any one of SEQ ID NOs: 293-337 or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 293-337. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to a sequence having at least about 80% identity to any one of SEQ ID NOs: 293-337. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to a sequence having at least about 85% identity to any one of SEQ ID NOs: 293-337. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to a sequence having at least about 90% identity to any one of SEQ ID NOs: 293-337. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 95% identical to any one of SEQ ID NOs: 293-337. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 96% identical to any one of SEQ ID NOs: 293-337. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 97% identical to any one of SEQ ID NOs: 293-337. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 98% identical to any one of SEQ ID NOs: 293-337. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 99% identical to any one of SEQ ID NOs: 293-337. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is 100% identical to any one of SEQ ID NOs: 293-337.
[0294] In some embodiments, the guide polynucleotide hybridizes or targets a sequence within the TRBC2 gene or within an intron of an endogenous gene. In some embodiments, the guide polynucleotide hybridizes or targets a sequence according to any one of SEQ ID NOs: 338-382, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 338-382. In some embodiments, the guide polynucleotide hybridizes or targets a sequence having at least about 80% identity to any one of SEQ ID NOs: 338-382. In some embodiments, the guide polynucleotide hybridizes or targets a sequence having at least about 85% identity to any one of SEQ ID NOs: 338-382. In some embodiments, the guide polynucleotide hybridizes or targets a sequence having at least about 90% identity to any one of SEQ ID NOs: 338-382. In some embodiments, the guide polynucleotide hybridizes or targets a sequence having at least about 95% identity to any one of SEQ ID NOs: 338-382. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 96% identical to any one of SEQ ID NOs: 338-382. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 97% identical to any one of SEQ ID NOs: 338-382. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 98% identical to any one of SEQ ID NOs: 338-382. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 99% identical to any one of SEQ ID NOs: 338-382. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is 100% identical to any one of SEQ ID NOs: 338-382.
[0295] In some embodiments, the target gene is ANGPTL3. In some embodiments, the guide polynucleotide is encoded by any one of SEQ ID NOs: 383-477, 1392-1489, 2120-2215, and 2312-2350, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 383-477, 1392-1489, 2120-2215, and 2312-2350. In some embodiments, the guide polynucleotide comprises a sequence comprising at least about 46-80 contiguous nucleotides that is at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to any one of SEQ ID NOs: 383-477, 1392-1489, 2120-2215, and 2312-2350. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 80% identical to any one of SEQ ID NOs: 383-477, 1392-1489, 2120-2215, and 2312-2350. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 85% identical to any one of SEQ ID NOs: 383-477, 1392-1489, 2120-2215, and 2312-2350. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 90% identical to any one of SEQ ID NOs: 383-477, 1392-1489, 2120-2215, and 2312-2350. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 95% identical to any one of SEQ ID NOs: 383-477, 1392-1489, 2120-2215, and 2312-2350. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 96% identical to any one of SEQ ID NOs: 383-477, 1392-1489, 2120-2215, and 2312-2350. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 97% identical to any one of SEQ ID NOs: 383-477, 1392-1489, 2120-2215, and 2312-2350.In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 98% identical to any one of SEQ ID NOs: 383-477, 1392-1489, 2120-2215, and 2312-2350. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 99% identical to any one of SEQ ID NOs: 383-477, 1392-1489, 2120-2215, and 2312-2350. In some embodiments, the guide polynucleotide is encoded by a sequence that is 100% identical to any one of SEQ ID NOs: 383-477, 1392-1489, 2120-2215, and 2312-2350.
[0296] In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to the target nucleic acid sequence within the ANGPTL3 gene or within an intron of an endogenous gene. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to any one of SEQ ID NOs: 383-477, 1392-1489, 2120-2215, and 2312-2350, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 383-477, 1392-1489, 2120-2215, and 2312-2350. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to a sequence having at least about 80% identity to any one of SEQ ID NOs: 383-477, 1392-1489, 2120-2215, and 2312-2350. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 85% identical to any one of SEQ ID NOs: 383-477, 1392-1489, 2120-2215, and 2312-2350. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 90% identical to any one of SEQ ID NOs: 383-477, 1392-1489, 2120-2215, and 2312-2350. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 95% identical to any one of SEQ ID NOs: 383-477, 1392-1489, 2120-2215, and 2312-2350. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 96% identical to any one of SEQ ID NOs: 383-477, 1392-1489, 2120-2215, and 2312-2350. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 97% identical to any one of SEQ ID NOs: 383-477, 1392-1489, 2120-2215, and 2312-2350. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 98% identical to any one of SEQ ID NOs: 383-477, 1392-1489, 2120-2215, and 2312-2350. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 99% identical to any one of SEQ ID NOs: 383-477, 1392-1489, 2120-2215, and 2312-2350.In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that has 100% identity to any one of SEQ ID NOs: 383-477, 1392-1489, 2120-2215, and 2312-2350.
[0297] In some embodiments, the guide polynucleotide hybridizes or targets a sequence within the ANGPTL3 gene or within an intron of an endogenous gene. In some embodiments, the guide polynucleotide hybridizes or targets a sequence according to any one of SEQ ID NOs: 478-572, 1490-1587, 2216-2311, and 2351-2389, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 478-572, 1490-1587, 2216-2311, and 2351-2389. In some embodiments, the guide polynucleotide hybridizes or targets a sequence having at least about 80% identity to any one of SEQ ID NOs: 478-572, 1490-1587, 2216-2311, and 2351-2389. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 85% identical to any one of SEQ ID NOs: 478-572, 1490-1587, 2216-2311, and 2351-2389. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 90% identical to any one of SEQ ID NOs: 478-572, 1490-1587, 2216-2311, and 2351-2389. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 95% identical to any one of SEQ ID NOs: 478-572, 1490-1587, 2216-2311, and 2351-2389. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 96% identical to any one of SEQ ID NOs: 478-572, 1490-1587, 2216-2311, and 2351-2389. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 97% identical to any one of SEQ ID NOs: 478-572, 1490-1587, 2216-2311, and 2351-2389. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 98% identical to any one of SEQ ID NOs: 478-572, 1490-1587, 2216-2311, and 2351-2389. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 99% identical to any one of SEQ ID NOs: 478-572, 1490-1587, 2216-2311, and 2351-2389. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is 100% identical to any one of SEQ ID NOs: 478-572, 1490-1587, 2216-2311, and 2351-2389.
[0298] In some embodiments, the target gene is PCSK9. In some embodiments, the guide polynucleotide is encoded by any one of SEQ ID NOs: 573-587 and 1362-1376, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 573-587 and 1362-1376. In some embodiments, the guide polynucleotide comprises a sequence comprising at least about 46-80 contiguous nucleotides that is at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to any one of SEQ ID NOs: 573-587 and 1362-1376. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 80% identical to any one of SEQ ID NOs: 573-587 and 1362-1376. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 85% identical to any one of SEQ ID NOs: 573-587 and 1362-1376. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 90% identical to any one of SEQ ID NOs: 573-587 and 1362-1376. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 95% identical to any one of SEQ ID NOs: 573-587 and 1362-1376. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 96% identical to any one of SEQ ID NOs: 573-587 and 1362-1376. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 97% identical to any one of SEQ ID NOs: 573-587 and 1362-1376. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 98% identical to any one of SEQ ID NOs: 573-587 and 1362- 1376. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 99% identical to any one of SEQ ID NOs: 573-587 and 1362- 1376. In some embodiments, the guide polynucleotide is encoded by a sequence that is 100% identical to any one of SEQ ID NOs: 573-587 and 1362- 1376.
[0299] In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to the target nucleic acid sequence within the PCSK9 gene or within an intron of an endogenous gene. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to any one of SEQ ID NOs: 573-587 and 1362-1376, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 573-587 and 1362-1376. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to a sequence having at least about 80% identity to any one of SEQ ID NOs: 573-587 and 1362-1376. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to a sequence having at least about 85% identity to any one of SEQ ID NOs: 573-587 and 1362-1376. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 90% identical to any one of SEQ ID NOs: 573-587 and 1362-1376. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 95% identical to any one of SEQ ID NOs: 573-587 and 1362-1376. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 96% identical to any one of SEQ ID NOs: 573-587 and 1362-1376. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 97% identical to any one of SEQ ID NOs: 573-587 and 1362-1376. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 98% identical to any one of SEQ ID NOs: 573-587 and 1362-1376. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 99% identical to any one of SEQ ID NOs: 573-587 and 1362- 1376. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is 100% identical to any one of SEQ ID NOs: 573-587 and 1362-1376.
[0300] In some embodiments, the guide polynucleotide hybridizes or targets a sequence within the PCSK9 gene or within an intron of an endogenous gene. In some embodiments, the guide polynucleotide hybridizes or targets a sequence according to any one of SEQ ID NOs: 588-602 and 1377-1391, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 588-602 and 1377-1391. In some embodiments, the guide polynucleotide hybridizes or targets a sequence having at least about 80% identity to any one of SEQ ID NOs: 588-602 and 1377-1391. In some embodiments, the guide polynucleotide hybridizes or targets a sequence having at least about 85% identity to any one of SEQ ID NOs: 588-602 and 1377-1391. In some embodiments, the guide polynucleotide hybridizes or targets a sequence having at least about 90% identity to any one of SEQ ID NOs: 588-602 and 1377-1391. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 95% identical to any one of SEQ ID NOs: 588-602 and 1377-1391. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 96% identical to any one of SEQ ID NOs: 588-602 and 1377-1391. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 97% identical to any one of SEQ ID NOs: 588-602 and 1377-1391. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 98% identical to any one of SEQ ID NOs: 588-602 and 1377-1391. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 99% identical to any one of SEQ ID NOs: 588-602 and 1377-1391. In some embodiments, the guide polynucleotide hybridizes or targets a sequence with 100% identity to any one of SEQ ID NOs: 588-602 and 1377-1391.
[0301] In some embodiments, the target gene is VCP (e.g., VCP R155). In some embodiments, the guide polynucleotide is encoded by any one of SEQ ID NOs: 723-738 and 755-762, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 723-738 and 755-762. In some embodiments, the guide polynucleotide comprises a sequence comprising at least about 46-80 contiguous nucleotides that is at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to any one of SEQ ID NOs: 723-738 and 755-762. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 80% identical to any one of SEQ ID NOs: 723-738 and 755-762. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 85% identical to any one of SEQ ID NOs: 723-738 and 755-762. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 90% identical to any one of SEQ ID NOs: 723-738 and 755-762. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 95% identical to any one of SEQ ID NOs: 723-738 and 755-762. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 96% identical to any one of SEQ ID NOs: 723-738 and 755-762. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 97% identical to any one of SEQ ID NOs: 723-738 and 755-762. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 98% identical to any one of SEQ ID NOs: 723-738 and 755-762. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 99% identical to any one of SEQ ID NOs: 723-738 and 755-762. In some embodiments, the guide polynucleotide is encoded by a sequence that is 100% identical to any one of SEQ ID NOs: 723-738 and 755-762.
[0302] In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to the target nucleic acid sequence within the VCP gene or within an intron of an endogenous gene. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to any one of SEQ ID NOs: 723-738 and 755-762, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 723-738 and 755-762. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to a sequence having at least about 80% identity to any one of SEQ ID NOs: 723-738 and 755-762. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to a sequence having at least about 85% identity to any one of SEQ ID NOs: 723-738 and 755-762. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 90% identical to any one of SEQ ID NOs: 723-738 and 755-762. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 95% identical to any one of SEQ ID NOs: 723-738 and 755-762. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 96% identical to any one of SEQ ID NOs: 723-738 and 755-762. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 97% identical to any one of SEQ ID NOs: 723-738 and 755-762. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 98% identical to any one of SEQ ID NOs: 723-738 and 755-762. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 99% identical to any one of SEQ ID NOs: 723-738 and 755-762. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is 100% identical to any one of SEQ ID NOs: 723-738 and 755-762.
[0303] In some embodiments, the guide polynucleotide hybridizes or targets a sequence within a VCP gene or within an intron of an endogenous gene. In some embodiments, the guide polynucleotide hybridizes or targets a sequence according to any one of SEQ ID NOs: 739-754 and 763-770, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 739-754 and 763-770. In some embodiments, the guide polynucleotide hybridizes or targets a sequence having at least about 80% identity to any one of SEQ ID NOs: 739-754 and 763-770. In some embodiments, the guide polynucleotide hybridizes or targets a sequence having at least about 85% identity to any one of SEQ ID NOs: 739-754 and 763-770. In some embodiments, the guide polynucleotide hybridizes or targets a sequence having at least about 90% identity to any one of SEQ ID NOs: 739-754 and 763-770. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 95% identical to any one of SEQ ID NOs: 739-754 and 763-770. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 96% identical to any one of SEQ ID NOs: 739-754 and 763-770. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 97% identical to any one of SEQ ID NOs: 739-754 and 763-770. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 98% identical to any one of SEQ ID NOs: 739-754 and 763-770. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 99% identical to any one of SEQ ID NOs: 739-754 and 763-770. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is 100% identical to any one of SEQ ID NOs: 739-754 and 763-770.
[0304] In some embodiments, the target locus is AAVS1. In some embodiments, the guide polynucleotide is encoded by any one of SEQ ID NOs: 928-949 and 1012-1049, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 928-949 and 1012-1049. In some embodiments, the guide polynucleotide comprises a sequence comprising at least about 46-80 contiguous nucleotides that is at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to any one of SEQ ID NOs: 928-949 and 1012-1049. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 80% identical to any one of SEQ ID NOs: 928-949 and 1012-1049. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 85% identical to any one of SEQ ID NOs: 928-949 and 1012-1049. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 90% identical to any one of SEQ ID NOs: 928-949 and 1012-1049. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 95% identical to any one of SEQ ID NOs: 928-949 and 1012-1049. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 96% identical to any one of SEQ ID NOs: 928-949 and 1012-1049. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 97% identical to any one of SEQ ID NOs: 928-949 and 1012-1049. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 98% identical to any one of SEQ ID NOs: 928-949 and 1012- 1049. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 99% identical to any one of SEQ ID NOs: 928-949 and 1012- 1049. In some embodiments, the guide polynucleotide is encoded by a sequence that is 100% identical to any one of SEQ ID NOs: 928-949 and 1012- 1049.
[0305] In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to the target nucleic acid sequence within the AAVS1 locus or within an intron of an endogenous gene. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to any one of SEQ ID NOs: 928-949 and 1012-1049, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 928-949 and 1012-1049. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to a sequence having at least about 80% identity to any one of SEQ ID NOs: 928-949 and 1012-1049. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to a sequence having at least about 85% identity to any one of SEQ ID NOs: 928-949 and 1012-1049. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 90% identical to any one of SEQ ID NOs: 928-949 and 1012-1049. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 95% identical to any one of SEQ ID NOs: 928-949 and 1012-1049. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 96% identical to any one of SEQ ID NOs: 928-949 and 1012-1049. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 97% identical to any one of SEQ ID NOs: 928-949 and 1012-1049. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 98% identical to any one of SEQ ID NOs: 928-949 and 1012-1049. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 99% identical to any one of SEQ ID NOs: 928-949 and 1012- 1049. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is 100% identical to any one of SEQ ID NOs: 928-949 and 1012-1049.
[0306] In some embodiments, the guide polynucleotide hybridizes or targets a sequence within the AAVS1 locus or within an intron of an endogenous gene. In some embodiments, the guide polynucleotide hybridizes or targets a sequence according to any one of SEQ ID NOs: 950-971 and 1050-1087, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 950-971 and 1050-1087. In some embodiments, the guide polynucleotide hybridizes or targets a sequence having at least about 80% identity to any one of SEQ ID NOs: 950-971 and 1050-1087. In some embodiments, the guide polynucleotide hybridizes or targets a sequence having at least about 85% identity to any one of SEQ ID NOs: 950-971 and 1050-1087. In some embodiments, the guide polynucleotide hybridizes or targets a sequence having at least about 90% identity to any one of SEQ ID NOs: 950-971 and 1050-1087. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 95% identical to any one of SEQ ID NOs: 950-971 and 1050-1087. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 96% identical to any one of SEQ ID NOs: 950-971 and 1050-1087. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 97% identical to any one of SEQ ID NOs: 950-971 and 1050-1087. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 98% identical to any one of SEQ ID NOs: 950-971 and 1050-1087. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 99% identical to any one of SEQ ID NOs: 950-971 and 1050-1087. In some embodiments, the guide polynucleotide hybridizes or targets a sequence with 100% identity to any one of SEQ ID NOs: 950-971 and 1050-1087.
[0307] In some embodiments, the target gene is GPR146. In some embodiments, the guide polynucleotide is encoded by any one of SEQ ID NOs: 1588-1656, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 1588-1656. In some embodiments, the guide polynucleotide comprises a sequence comprising at least about 46-80 contiguous nucleotides that is at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to any one of SEQ ID NOs: 1588-1656. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 80% identical to any one of SEQ ID NOs: 1588-1656. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 85% identical to any one of SEQ ID NOs: 1588-1656. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 90% identical to any one of SEQ ID NOs: 1588-1656. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 95% identical to any one of SEQ ID NOs: 1588-1656. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 96% identical to any one of SEQ ID NOs: 1588-1656. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 97% identical to any one of SEQ ID NOs: 1588-1656. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 98% identical to any one of SEQ ID NOs: 1588-1656. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 99% identical to any one of SEQ ID NOs: 1588-1656. In some embodiments, the guide polynucleotide is encoded by a sequence that is 100% identical to any one of SEQ ID NOs: 1588-1656.
[0308] In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to the target nucleic acid sequence within the GPR146 gene or within an intron of an endogenous gene. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to any one of SEQ ID NOs: 1588-1656 or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 1588-1656. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to a sequence having at least about 80% identity to any one of SEQ ID NOs: 1588-1656. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to a sequence having at least about 85% identity to any one of SEQ ID NOs: 1588-1656. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to a sequence having at least about 90% identity to any one of SEQ ID NOs: 1588-1656. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 95% identical to any one of SEQ ID NOs: 1588-1656. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 96% identical to any one of SEQ ID NOs: 1588-1656. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 97% identical to any one of SEQ ID NOs: 1588-1656. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 98% identical to any one of SEQ ID NOs: 1588-1656. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 99% identical to any one of SEQ ID NOs: 1588-1656. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is 100% identical to any one of SEQ ID NOs: 1588-1656.
[0309] In some embodiments, the guide polynucleotide hybridizes or targets a sequence within the GPR146 gene or within an intron of an endogenous gene. In some embodiments, the guide polynucleotide hybridizes or targets a sequence according to any one of SEQ ID NOs: 1657-1725 or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 1657-1725. In some embodiments, the guide polynucleotide hybridizes or targets a sequence having at least about 80% identity to any one of SEQ ID NOs: 1657-1725. In some embodiments, the guide polynucleotide hybridizes or targets a sequence having at least about 85% identity to any one of SEQ ID NOs: 1657-1725. In some embodiments, the guide polynucleotide hybridizes or targets a sequence having at least about 90% identity to any one of SEQ ID NOs: 1657-1725. In some embodiments, the guide polynucleotide hybridizes or targets a sequence having at least about 95% identity to any one of SEQ ID NOs: 1657-1725. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 96% identical to any one of SEQ ID NOs: 1657-1725. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 97% identical to any one of SEQ ID NOs: 1657-1725. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 98% identical to any one of SEQ ID NOs: 1657-1725. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 99% identical to any one of SEQ ID NOs: 1657-1725. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is 100% identical to any one of SEQ ID NOs: 1657-1725.
[0310] In some embodiments, the target gene is APOA1. In some embodiments, the guide polynucleotide is encoded by any one of SEQ ID NOs: 1726-1744, 1764-1774, 1866-1961, and 2058-2088, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 1726-1744, 1764-1774, 1866-1961, and 2058-2088. In some embodiments, the guide polynucleotide comprises a sequence comprising at least about 46-80 contiguous nucleotides that is at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to any one of SEQ ID NOs: 1726-1744, 1764-1774, 1866-1961, and 2058-2088. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 80% identical to any one of SEQ ID NOs: 1726-1744, 1764-1774, 1866-1961, and 2058-2088. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 85% identical to any one of SEQ ID NOs: 1726-1744, 1764-1774, 1866-1961, and 2058-2088. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 90% identical to any one of SEQ ID NOs: 1726-1744, 1764-1774, 1866-1961, and 2058-2088. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 95% identical to any one of SEQ ID NOs: 1726-1744, 1764-1774, 1866-1961, and 2058-2088. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 96% identical to any one of SEQ ID NOs: 1726-1744, 1764-1774, 1866-1961, and 2058-2088. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 97% identical to any one of SEQ ID NOs: 1726-1744, 1764-1774, 1866-1961, and 2058-2088.In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 98% identical to any one of SEQ ID NOs: 1726-1744, 1764-1774, 1866-1961, and 2058-2088. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 99% identical to any one of SEQ ID NOs: 1726-1744, 1764-1774, 1866-1961, and 2058-2088. In some embodiments, the guide polynucleotide is encoded by a sequence that is 100% identical to any one of SEQ ID NOs: 1726-1744, 1764-1774, 1866-1961, and 2058-2088.
[0311] In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to the target nucleic acid sequence within the APOA1 gene or within an intron of an endogenous gene. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to any one of SEQ ID NOs: 1726-1744, 1764-1774, 1866-1961, and 2058-2088, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 1726-1744, 1764-1774, 1866-1961, and 2058-2088. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to a sequence having at least about 80% identity to any one of SEQ ID NOs: 1726-1744, 1764-1774, 1866-1961, and 2058-2088. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 85% identical to any one of SEQ ID NOs: 1726-1744, 1764-1774, 1866-1961, and 2058-2088. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 90% identical to any one of SEQ ID NOs: 1726-1744, 1764-1774, 1866-1961, and 2058-2088. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 95% identical to any one of SEQ ID NOs: 1726-1744, 1764-1774, 1866-1961, and 2058-2088. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 96% identical to any one of SEQ ID NOs: 1726-1744, 1764-1774, 1866-1961, and 2058-2088. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 97% identical to any one of SEQ ID NOs: 1726-1744, 1764-1774, 1866-1961, and 2058-2088. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 98% identical to any one of SEQ ID NOs: 1726-1744, 1764-1774, 1866-1961, and 2058-2088. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 99% identical to any one of SEQ ID NOs: 1726-1744, 1764-1774, 1866-1961, and 2058-2088.In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that has 100% identity to any one of SEQ ID NOs: 1726-1744, 1764-1774, 1866-1961, and 2058-2088.
[0312] In some embodiments, the guide polynucleotide hybridizes or targets a sequence within the APOA1 gene or within an intron of an endogenous gene. In some embodiments, the guide polynucleotide hybridizes or targets a sequence according to any one of SEQ ID NOs: 1745-1763, 1775-1785, 1962-2057, and 2089-2119, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 1745-1763, 1775-1785, 1962-2057, and 2089-2119. In some embodiments, the guide polynucleotide hybridizes or targets a sequence having at least about 80% identity to any one of SEQ ID NOs: 1745-1763, 1775-1785, 1962-2057, and 2089-2119. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 85% identical to any one of SEQ ID NOs: 1745-1763, 1775-1785, 1962-2057, and 2089-2119. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 90% identical to any one of SEQ ID NOs: 1745-1763, 1775-1785, 1962-2057, and 2089-2119. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 95% identical to any one of SEQ ID NOs: 1745-1763, 1775-1785, 1962-2057, and 2089-2119. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 96% identical to any one of SEQ ID NOs: 1745-1763, 1775-1785, 1962-2057, and 2089-2119. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 97% identical to any one of SEQ ID NOs: 1745-1763, 1775-1785, 1962-2057, and 2089-2119. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 98% identical to any one of SEQ ID NOs: 1745-1763, 1775-1785, 1962-2057, and 2089-2119. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is at least about 99% identical to any one of SEQ ID NOs: 1745-1763, 1775-1785, 1962-2057, and 2089-2119.In some embodiments, the guide polynucleotide hybridizes or targets a sequence with 100% identity to any one of SEQ ID NOs: 1745-1763, 1775-1785, 1962-2057, and 2089-2119.
[0313] In some embodiments, the target gene is HAO1. In some embodiments, the guide polynucleotide is encoded by any one of SEQ ID NOs: 611-633, 1789-1826, and 1827-1865, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 611-633, 1789-1826, and 1827-1865. In some embodiments, the guide polynucleotide comprises a sequence comprising at least about 46-80 contiguous nucleotides that is at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to any one of SEQ ID NOs: 611-633, 1789-1826, and 1827-1865. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 80% identical to any one of SEQ ID NOs: 611-633, 1789-1826, and 1827-1865. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 85% identical to any one of SEQ ID NOs: 611-633, 1789-1826, and 1827-1865. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 90% identical to any one of SEQ ID NOs: 611-633, 1789-1826, and 1827-1865. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 95% identical to any one of SEQ ID NOs: 611-633, 1789-1826, and 1827-1865. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 96% identical to any one of SEQ ID NOs: 611-633, 1789-1826, and 1827-1865. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 97% identical to any one of SEQ ID NOs: 611-633, 1789-1826, and 1827-1865. In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 98% identical to any one of SEQ ID NOs: 611-633, 1789-1826, and 1827-1865.In some embodiments, the guide polynucleotide is encoded by a sequence that is at least about 99% identical to any one of SEQ ID NOs: 611-633, 1789-1826, and 1827-1865. In some embodiments, the guide polynucleotide is encoded by a sequence that is 100% identical to any one of SEQ ID NOs: 611-633, 1789-1826, and 1827-1865.
[0314] In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to the target nucleic acid sequence within the HAO1 gene or within an intron of an endogenous gene. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to any one of SEQ ID NOs: 611-633, 1789-1826, and 1827-1865, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 611-633, 1789-1826, and 1827-1865. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to a sequence having at least about 80% identity to any one of SEQ ID NOs: 611-633, 1789-1826, and 1827-1865. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 85% identical to any one of SEQ ID NOs: 611-633, 1789-1826, and 1827-1865. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 90% identical to any one of SEQ ID NOs: 611-633, 1789-1826, and 1827-1865. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 95% identical to any one of SEQ ID NOs: 611-633, 1789-1826, and 1827-1865. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 96% identical to any one of SEQ ID NOs: 611-633, 1789-1826, and 1827-1865. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 97% identical to any one of SEQ ID NOs: 611-633, 1789-1826, and 1827-1865. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 98% identical to any one of SEQ ID NOs: 611-633, 1789-1826, and 1827-1865. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is at least about 99% identical to any one of SEQ ID NOs: 611-633, 1789-1826, and 1827-1865. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to a sequence that is 100% identical to any one of SEQ ID NOs: 611-633, 1789-1826, and 1827-1865.
[0315] In some embodiments, the guide polynucleotide (e.g., guide RNA) includes various structural elements, including but not limited to: a spacer sequence, crRNA, and optional tracrRNA that binds to the protospacer sequence (target sequence). In some embodiments, the genome editing system includes a CRISPR guide RNA. In some embodiments, the guide RNA includes a crRNA that includes a spacer sequence. In some embodiments, the guide RNA further includes tracrRNA or modified tracrRNA.
[0316] In some embodiments, the systems provided herein include one or more guide RNAs. In some embodiments, the guide RNA includes a sense sequence. In some embodiments, the guide RNA includes an antisense sequence. In some embodiments, the guide RNA includes a nucleotide sequence other than a region complementary or substantially complementary to a region of the target sequence. For example, a crRNA is or is considered to be part of a guide RNA, or is included in a guide RNA, such as a crRNA:tracrRNA chimera.
[0317] In some embodiments, the guide RNA comprises synthetic nucleotides or modified nucleotides. In some embodiments, the guide RNA comprises one or more internucleoside linkers modified by natural phosphodiester. In some embodiments, all internucleoside linkers of the guide RNA or its continuous nucleotide sequence are modified. For example, in some embodiments, the internucleoside bond comprises sulfur (S), such as a phosphorothioate internucleoside bond. In some embodiments, the guide RNA comprises greater than about 10%, 25%, 50%, 75% or 90% modified internucleoside linkers. In some embodiments, the guide RNA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more than 10 modified internucleoside linkers (e.g., phosphorothioate internucleoside bonds).
[0318] In some embodiments, the guide RNA includes modifications to ribose sugar or core bases. In some embodiments, the guide RNA includes one or more nucleosides, the nucleosides including modified sugar moieties, wherein when compared to the ribose sugar moieties present in deoxyribonucleic acid (DNA) and RNA, the modified glucose moiety is a modification of the sugar moiety. In some embodiments, the modification is within the ribose ring structure. Exemplary modifications include, but are not limited to, replacement with a hexose ring (HNA), a bicyclic ring (e.g., locked nucleic acid (LNA)) having a diradical bridge between the C2 carbon and the C4 carbon on the ribose ring, or an unconnected ribose ring (e.g., UNA) that typically lacks a bond between the C2 carbon and the C3 carbon. In some embodiments, sugar-modified nucleosides include bicyclohexose nucleic acids or tricyclic nucleic acids. In some embodiments, modified nucleosides include nucleosides in which the sugar moiety is replaced by a non-sugar moiety, such as peptide nucleic acids (PNA) or morpholino nucleic acids.
[0319] In some embodiments, the guide RNA includes one or more modified sugars. In some embodiments, sugar modifications include modifications by changing the substituents on the ribose ring to groups other than hydrogen or 2'-OH groups naturally present in DNA and RNA nucleosides. In some embodiments, substituents are introduced at the 2', 3', 4', 5' positions or a combination thereof. In some embodiments, nucleosides with modified sugar moieties include 2'-modified nucleosides, for example, 2'-substituted nucleosides. In some embodiments, 2' sugar-modified nucleosides are nucleosides with substituents other than H or -OH at the 2' position (2'-substituted nucleosides) or including 2'-connected diradicals, and include 2'-substituted nucleosides and LNA (2'-4' diradical bridged) nucleosides. Examples of 2'-substituted modified nucleosides include, but are not limited to, 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA (MOE), 2'-amino-DNA, 2'-fluoro-RNA, and 2'-F-ANA nucleosides. In some embodiments, the modification in the ribose group comprises a modification at the 2' position of the ribose group. In some embodiments, the modification at the 2' position of the ribose group is selected from the group consisting of: 2'-O-methyl, 2'-fluoro, 2'-deoxy, and 2'-O-(2-methoxyethyl).
[0320] In some embodiments, the guide RNA includes one or more modified sugars. In some embodiments, the guide RNA includes only modified sugars. In some embodiments, the guide RNA includes greater than about 10%, 25%, 50%, 75% or 90% modified sugars. In some embodiments, the modified sugar is a bicyclic sugar. In some embodiments, the modified sugar includes 2'-O-methyl. In some embodiments, the modified sugar includes 2'-fluoro. In some embodiments, the modified sugar includes 2'-O-methoxyethyl. In some embodiments, the guide RNA includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more than 10 modified sugars (e.g., including 2'-O-methyl or 2'-fluoro).
[0321] In some embodiments, the guide RNA includes both internucleoside linker modifications and nucleoside modifications. In some embodiments, the guide RNA includes greater than about 10%, 25%, 50%, 75%, or 90% modified internucleoside linkers and greater than about 10%, 25%, 50%, 75%, or 90% modified sugars. In some embodiments, the guide RNA includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 modified internucleoside linkers (e.g., phosphorothioate internucleoside bonds) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 modified sugars (e.g., including 2'-O-methyl or 2'-fluoro).
[0322] In some cases, the guide RNA comprises a sequence complementary to a polynucleotide sequence of a eukaryotic, fungal, plant, mammalian, or human genome. In some cases, the guide RNA comprises a sequence complementary to a polynucleotide sequence of a eukaryotic genome. In some cases, the guide RNA comprises a sequence complementary to a polynucleotide sequence of a fungal genome. In some cases, the guide RNA comprises a sequence complementary to a polynucleotide sequence of a plant genome. In some cases, the guide RNA comprises a sequence complementary to a polynucleotide sequence of a mammalian genome. In some cases, the guide RNA comprises a sequence complementary to a polynucleotide sequence of a human genome.
[0323] In some embodiments, the guide RNA is 30-250 nucleotides in length. In some embodiments, the guide RNA is greater than 90 nucleotides in length. In some embodiments, the guide RNA is less than 245 nucleotides in length. In some embodiments, the guide RNA is 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 220, 240, or greater than 240 nucleotides in length. In some embodiments, the guide RNA is about 30 to about 40, about 30 to about 50, about 30 to about 60, about 30 to about 70, about 30 to about 80, about 30 to about 90, about 30 to about 100, about 30 to about 120, about 30 to about 140, about 30 to about 160, about 30 to about 180, about 30 to about 200, about 30 to about 220, about 30 to about 240, about 50 to about 60, about 50 to about 70, about 50 to about 80, about 50 to about 90, about 50 to about 100, about 30 to about 120, about 30 to about 140, about 30 to about 160, about 30 to about 180, about 30 to about 200, about 30 to about 220, about 30 to about 240, about 50 to about 60, about 50 to about 70, about 50 to about 80, about 50 to about 90, about 50 to about 100 In some embodiments, the present invention relates to a polypeptide having at least one nucleotide sequence and at least one nucleotide sequence. In some embodiments, the present invention relates to a polypeptide having at least one nucleotide sequence and at least one nucleotide sequence. In some embodiments, the present invention relates to a polypeptide having at least one nucleotide sequence and at least one nucleotide sequence.
[0324] MG endonuclease system
[0325] In certain embodiments, described herein are engineered nuclease systems comprising an engineered endonuclease and an engineered guide polynucleotide configured to form a complex with the endonuclease and hybridize to a target nucleic acid sequence.
[0326] In some embodiments, the engineered nuclease system comprises an engineered endonuclease and an engineered guide polynucleotide, the engineered endonuclease comprising a sequence having at least about 70% identity to any one of SEQ ID NOs: 1-27 and 771-862. In some embodiments, the engineered nuclease system comprises an engineered endonuclease and an engineered guide polynucleotide, the engineered endonuclease comprising a sequence having at least about 75% identity to any one of SEQ ID NOs: 1-27 and 771-862. In some embodiments, the engineered nuclease system comprises an engineered endonuclease and an engineered guide polynucleotide, the engineered endonuclease comprising a sequence having at least about 80% identity to any one of SEQ ID NOs: 1-27 and 771-862. In some embodiments, the engineered nuclease system comprises an engineered endonuclease and an engineered guide polynucleotide, the engineered endonuclease comprising a sequence having at least about 85% identity to any one of SEQ ID NOs: 1-27 and 771-862. In some embodiments, the engineered nuclease system comprises an engineered endonuclease and an engineered guide polynucleotide, the engineered endonuclease comprising a sequence having at least about 90% identity to any one of SEQ ID NOs: 1-27 and 771-862. In some embodiments, the engineered nuclease system comprises an engineered endonuclease and an engineered guide polynucleotide, the engineered endonuclease comprising a sequence having at least about 95% identity to any one of SEQ ID NOs: 1-27 and 771-862. In some embodiments, the engineered nuclease system comprises an engineered endonuclease and an engineered guide polynucleotide, the engineered endonuclease comprising a sequence having at least about 96% identity to any one of SEQ ID NOs: 1-27 and 771-862. In some embodiments, the engineered nuclease system comprises an engineered endonuclease and an engineered guide polynucleotide, the engineered endonuclease comprising a sequence having at least about 97% identity to any one of SEQ ID NOs: 1-27 and 771-862. In some embodiments, the engineered nuclease system comprises an engineered endonuclease comprising a sequence at least about 98% identical to any one of SEQ ID NOs: 1-27 and 771-862 and an engineered guide polynucleotide. In some embodiments, the engineered nuclease system comprises an engineered endonuclease comprising a sequence at least about 99% identical to any one of SEQ ID NOs: 1-27 and 771-862 and an engineered guide polynucleotide.In some embodiments, an engineered nuclease system comprises an engineered endonuclease comprising 100% identity to any one of SEQ ID NOs: 1-27 and 771-862 and an engineered guide polynucleotide.
[0327] In some embodiments, the engineered nuclease system comprises an engineered endonuclease comprising a sequence having at least about 70% identity to any one of SEQ ID NOs: 109-110 and 2842-2854 and an engineered guide polynucleotide. In some embodiments, the engineered nuclease system comprises an engineered endonuclease comprising a sequence having at least about 75% identity to any one of SEQ ID NOs: 109-110 and 2842-2854 and an engineered guide polynucleotide. In some embodiments, the engineered nuclease system comprises an engineered endonuclease comprising a sequence having at least about 80% identity to any one of SEQ ID NOs: 109-110 and 2842-2854 and an engineered guide polynucleotide. In some embodiments, the engineered nuclease system comprises an engineered endonuclease comprising a sequence having at least about 85% identity to any one of SEQ ID NOs: 109-110 and 2842-2854 and an engineered guide polynucleotide. In some embodiments, the engineered nuclease system comprises an engineered endonuclease comprising a sequence having at least about 90% identity to any one of SEQ ID NOs: 109-110 and 2842-2854 and an engineered guide polynucleotide. In some embodiments, the engineered nuclease system comprises an engineered endonuclease comprising a sequence having at least about 95% identity to any one of SEQ ID NOs: 109-110 and 2842-2854 and an engineered guide polynucleotide. In some embodiments, the engineered nuclease system comprises an engineered endonuclease comprising a sequence having at least about 96% identity to any one of SEQ ID NOs: 109-110 and 2842-2854 and an engineered guide polynucleotide. In some embodiments, the engineered nuclease system comprises an engineered endonuclease comprising a sequence having at least about 97% identity to any one of SEQ ID NOs: 109-110 and 2842-2854 and an engineered guide polynucleotide. In some embodiments, the engineered nuclease system comprises an engineered endonuclease comprising a sequence having at least about 98% identity to any one of SEQ ID NOs: 109-110 and 2842-2854 and an engineered guide polynucleotide. In some embodiments, an engineered nuclease system comprises an engineered endonuclease comprising a sequence at least about 99% identical to any one of SEQ ID NOs: 109-110 and 2842-2854 and an engineered guide polynucleotide.In some embodiments, an engineered nuclease system comprises an engineered endonuclease comprising 100% identity to any one of SEQ ID NOs: 109-110 and 2842-2854 and an engineered guide polynucleotide.
[0328] In some embodiments, the engineered guide polynucleotide is a single guide nucleic acid. In some embodiments, the engineered guide polynucleotide is a dual guide nucleic acid. In some embodiments, the engineered guide polynucleotide is RNA. In some embodiments, the engineered endonuclease is non-covalently bound to the engineered guide polynucleotide. In some embodiments, the endonuclease is covalently linked to the engineered guide polynucleotide.
[0329] In some embodiments, an engineered nuclease system comprises an endonuclease comprising a sequence at least about 70% identical to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within an albumin gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence at least about 70% identical to any one of SEQ ID NOs: 67-86. In some embodiments, an engineered nuclease system comprises an endonuclease comprising a sequence at least about 75% identical to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within an albumin gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence at least about 75% identical to any one of SEQ ID NOs: 67-86. In some embodiments, an engineered nuclease system comprises an endonuclease comprising a sequence at least about 80% identical to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within an albumin gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence at least about 80% identical to any one of SEQ ID NOs: 67-86. In some embodiments, an engineered nuclease system comprises an endonuclease comprising a sequence at least about 85% identical to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within an albumin gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence at least about 85% identical to any one of SEQ ID NOs: 67-86.In some embodiments, an engineered nuclease system comprises an endonuclease comprising a sequence at least about 90% identical to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within an albumin gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence at least about 90% identical to any one of SEQ ID NOs: 67-86. In some embodiments, an engineered nuclease system comprises an endonuclease comprising a sequence at least about 95% identical to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within an albumin gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence at least about 95% identical to any one of SEQ ID NOs: 67-86. In some embodiments, an engineered nuclease system comprises an endonuclease comprising a sequence at least about 96% identical to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within an albumin gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence at least about 96% identical to any one of SEQ ID NOs: 67-86. In some embodiments, an engineered nuclease system comprises an endonuclease comprising a sequence at least about 97% identical to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within an albumin gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence at least about 97% identical to any one of SEQ ID NOs: 67-86.In some embodiments, an engineered nuclease system comprises an endonuclease comprising a sequence at least about 98% identical to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within an albumin gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence at least about 98% identical to any one of SEQ ID NOs: 67-86. In some embodiments, an engineered nuclease system comprises an endonuclease comprising a sequence at least about 99% identical to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within an albumin gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence at least about 99% identical to any one of SEQ ID NOs: 67-86. In some embodiments, an engineered nuclease system comprises an endonuclease comprising 100% identity to any one of SEQ ID NOs: 1-27 and 771-862 and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within an albumin gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising 100% identity to any one of SEQ ID NOs: 67-86. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to any one of SEQ ID NOs: 67-86, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 67-86.
[0330] In some embodiments, an engineered nuclease system comprises an endonuclease comprising a sequence having at least about 70% identity to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a TRAC gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least about 70% identity to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617. In some embodiments, an engineered nuclease system comprises an endonuclease comprising a sequence at least about 75% identical to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a TRAC gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence at least about 75% identical to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617. In some embodiments, an engineered nuclease system comprises an endonuclease comprising a sequence at least about 80% identical to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a TRAC gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence at least about 80% identical to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617.In some embodiments, an engineered nuclease system comprises an endonuclease comprising a sequence at least about 85% identical to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a TRAC gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence at least about 85% identical to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617. In some embodiments, an engineered nuclease system comprises an endonuclease comprising a sequence at least about 90% identical to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a TRAC gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence at least about 90% identical to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617. In some embodiments, an engineered nuclease system comprises an endonuclease comprising a sequence at least about 95% identical to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a TRAC gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence at least about 95% identical to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617.In some embodiments, an engineered nuclease system comprises an endonuclease comprising a sequence having at least about 96% identity to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a TRAC gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least about 96% identity to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617. In some embodiments, an engineered nuclease system comprises an endonuclease comprising a sequence having at least about 97% identity to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a TRAC gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least about 97% identity to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617. In some embodiments, an engineered nuclease system comprises an endonuclease comprising a sequence at least about 98% identical to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a TRAC gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence at least about 98% identical to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617.In some embodiments, an engineered nuclease system comprises an endonuclease comprising a sequence at least about 99% identical to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a TRAC gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence at least about 99% identical to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617. In some embodiments, an engineered nuclease system comprises an endonuclease comprising 100% identity to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a TRAC gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising 100% identity to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617. In some embodiments, the guide polynucleotide hybridizes or targets a sequence that is complementary to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617, or a sequence that has at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617.
[0331] In some embodiments, the guide polynucleotide hybridizes or targets a sequence according to any one of SEQ ID NOs: 139-158, 925-927, 992-1011, 1184-1279, 1321-1361, 2486-2581, and 2618-2653, or a sequence with at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 139-158, 925-927, 992-1011, 1184-1279, 1321-1361, 2486-2581, and 2618-2653. In some embodiments, the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 139-158, 925-927, 992-1011, 1184-1279, 1321-1361, 2486-2581, and 2618-2653.
[0332] In some embodiments, the engineered nuclease system comprises an endonuclease comprising a sequence having at least about 70% identity to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a B2M gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least about 70% identity to any one of SEQ ID NOs: 159-184. In some embodiments, the engineered nuclease system comprises an endonuclease comprising a sequence having at least about 75% identity to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a B2M gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least about 75% identity to any one of SEQ ID NOs: 159-184. In some embodiments, the engineered nuclease system comprises an endonuclease comprising a sequence at least about 80% identical to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a B2M gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence at least about 80% identical to any one of SEQ ID NOs: 159-184. In some embodiments, the engineered nuclease system comprises an endonuclease comprising a sequence having at least about 85% identity to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a B2M gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least about 85% identity to any one of SEQ ID NOs: 159-184.In some embodiments, the engineered nuclease system comprises an endonuclease comprising a sequence at least about 90% identical to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a B2M gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence at least about 90% identical to any one of SEQ ID NOs: 159-184. In some embodiments, the engineered nuclease system comprises an endonuclease comprising a sequence at least about 95% identical to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a B2M gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence at least about 95% identical to any one of SEQ ID NOs: 159-184. In some embodiments, the engineered nuclease system comprises an endonuclease comprising a sequence having at least about 96% identity to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a B2M gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least about 96% identity to any one of SEQ ID NOs: 159-184. In some embodiments, the engineered nuclease system comprises an endonuclease comprising a sequence having at least about 97% identity to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a B2M gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least about 97% identity to any one of SEQ ID NOs: 159-184.In some embodiments, the engineered nuclease system comprises an endonuclease comprising a sequence at least about 98% identical to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a B2M gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence at least about 98% identical to any one of SEQ ID NOs: 159-184. In some embodiments, the engineered nuclease system comprises an endonuclease comprising a sequence at least about 99% identical to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a B2M gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence at least about 99% identical to any one of SEQ ID NOs: 159-184. In some embodiments, the engineered nuclease system comprises an endonuclease comprising 100% identity to any one of SEQ ID NOs: 1-27 and 771-862 and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a B2M gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising 100% identity to any one of SEQ ID NOs: 159-184. In some embodiments, the guide polynucleotide hybridizes or targets a sequence complementary to any one of SEQ ID NOs: 159-184, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 159-184.
[0333] In some embodiments, the guide polynucleotide hybridizes or targets a sequence according to any one of SEQ ID NOs: 185-210, or a sequence having at least 90%, 95%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 185-210. In some embodiments, the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 185-210.
[0334] In some embodiments, the engineered nuclease system comprises a nuclease comprising a sequence having at least about 70% identity to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide, the engineered guide polynucleotide being configured to form a complex with the nuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a TRBC1 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least about 70% identity to any one of SEQ ID NOs: 211-251. In some embodiments, the engineered nuclease system comprises a nuclease comprising a sequence having at least about 75% identity to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide, the engineered guide polynucleotide being configured to form a complex with the nuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a TRBC1 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least about 75% identity to any one of SEQ ID NOs: 211-251. In some embodiments, the engineered nuclease system comprises an endonuclease comprising a sequence having at least about 80% identity to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a TRBC1 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least about 80% identity to any one of SEQ ID NOs: 211-251. In some embodiments, the engineered nuclease system comprises an endonuclease comprising a sequence having at least about 85% identity to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a TRBC1 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least about 85% identity to any one of SEQ ID NOs: 211-251.In some embodiments, the engineered nuclease system comprises a nuclease comprising a sequence at least about 90% identical to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the nuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a TRBC1 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence at least about 90% identical to any one of SEQ ID NOs: 211-251. In some embodiments, the engineered nuclease system comprises an endonuclease comprising a sequence at least about 95% identical to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the endonuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a TRBC1 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence at least about 95% identical to any one of SEQ ID NOs: 211-251. In some embodiments, the engineered nuclease system comprises a nuclease comprising a sequence having at least about 96% identity to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide configured to form a complex with the nuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a TRBC1 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least about 96% identity to any one of SEQ ID NOs: 211-251. In some embodiments, the engineered nuclease system comprises a nuclease comprising a sequence having at least about 97% identity to any one of SEQ ID NOs: 1-27 and 771-862, and an engineered guide polynucleotide, the engineered guide polynucleotide being configured to form a complex with the nuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a TRBC1 gene or within an intron of...
Claims
1. An engineered endonuclease, comprising: a) an N-terminal portion comprising a sequence having at least 80% sequence identity to SEQ ID NO: 696; as well as b) a C-terminal portion comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 697-721.
2. The engineered nuclease of claim 1, wherein the N-terminal portion and the C-terminal portion are fused directly to each other.
3. The engineered nuclease of claim 1, wherein the N-terminal portion and the C-terminal portion are joined by a linker.
4. The engineered endonuclease of claim 3, wherein the linker is a glycine and / or serine-rich linker, a large protein domain, a long helical structure, or a short helical structure.
5. The engineered nuclease according to any one of claims 3 to 4, wherein the linker is (GGGGS)n, and wherein n is an integer from 1 to 20.
6. The engineered nuclease according to any one of claims 3 to 4, wherein the linker is GGGGS (SEQ ID NO: 2864).
7. The engineered nuclease of any one of claims 1 to 6, wherein the N-terminal portion comprises a sequence having at least 90% sequence identity to SEQ ID NO:
696.
8. The engineered nuclease according to any one of claims 1 to 6, wherein the N-terminal portion comprises a sequence having 100% sequence identity to SEQ ID NO:
696.
9. The engineered endonuclease of any one of claims 1 to 8, wherein the C-terminal portion comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 697-721.
10. The engineered endonuclease of any one of claims 1 to 8, wherein the C-terminal portion comprises a sequence having 100% sequence identity to any one of SEQ ID NOs: 697-721.
11. The engineered endonuclease of any one of claims 1 to 10, wherein the engineered endonuclease is configured to bind to a PAM comprising any one of SEQ ID NOs: 60-66, 117, 865-919, and 2855-2863.
12. An engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862.
13. The engineered endonuclease of claim 12, wherein the engineered endonuclease comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862.
14. The engineered endonuclease of claim 12, wherein the engineered endonuclease comprises a sequence having 100% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862.
15. An engineered endonuclease comprising a sequence having at least 80% sequence identity to SEQ ID NO:
10.
16. The engineered endonuclease of claim 15, wherein the engineered endonuclease comprises a sequence having at least 90% sequence identity to SEQ ID NO:
10.
17. The engineered endonuclease of claim 15, wherein the engineered endonuclease comprises a sequence having 100% sequence identity to SEQ ID NO:
10.
18. An engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 109-110 and 2842-2854.
19. The engineered endonuclease of claim 18, wherein the engineered endonuclease comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 109-110 and 2842-2854.
20. The engineered endonuclease of claim 18, wherein the engineered endonuclease comprises a sequence having 100% sequence identity to any one of SEQ ID NOs: 109-110 and 2842-2854.
21. An engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the endonuclease and hybridize to a target nucleic acid sequence.
22. The engineered nuclease system of claim 21, wherein the engineered endonuclease comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862.
23. The engineered nuclease system of claim 21, wherein the engineered endonuclease comprises a sequence having 100% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862.
24. The engineered nuclease system of any one of claims 21 to 23, wherein the engineered guide polynucleotide is a single guide nucleic acid.
25. The engineered nuclease system of any one of claims 21 to 23, wherein the engineered guide polynucleotide is a dual guide nucleic acid.
26. The engineered nuclease system of any one of claims 21 to 23, wherein the engineered guide polynucleotide is RNA.
27. The engineered nuclease system of any one of claims 21 to 26, wherein the engineered endonuclease is non-covalently bound to the engineered guide polynucleotide.
28. The engineered nuclease system of any one of claims 21 to 26, wherein the endonuclease is covalently linked to the engineered guide polynucleotide.
29. The engineered nuclease system of any one of claims 21 to 26, wherein the endonuclease is fused to the engineered guide polynucleotide.
30. The engineered nuclease system of any one of claims 21 to 29, wherein the engineered guide polynucleotide comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 28-45, 605-610, 646-695, 863, and 1789-1826.
31. The engineered nuclease system of any one of claims 21 to 29, wherein the engineered guide polynucleotide comprises a sequence having 100% sequence identity to any one of SEQ ID NOs: 28-45, 605-610, 646-695, 863, and 1789-1826.
32. The engineered nuclease system of any one of claims 21 to 31, wherein the engineered endonuclease is configured to bind to a PAM comprising any one of SEQ ID NOs: 60-66, 865-919 and 2863.
33. An engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 109-110 and 2842-2854; and b) an engineered guide polynucleotide configured to form a complex with the endonuclease and hybridize to a target nucleic acid sequence.
34. The engineered nuclease system of claim 33, wherein the engineered endonuclease comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 109-110 and 2842-2854.
35. The engineered nuclease system of claim 33, wherein the engineered endonuclease comprises a sequence having 100% sequence identity to any one of SEQ ID NOs: 109-110 and 2842-2854.
36. The engineered nuclease system of any one of claims 33 to 35, wherein the engineered guide polynucleotide is a single guide nucleic acid.
37. The engineered nuclease system of any one of claims 33 to 35, wherein the engineered guide polynucleotide is a dual guide nucleic acid.
38. The engineered nuclease system of any one of claims 33 to 35, wherein the engineered guide polynucleotide is RNA.
39. The engineered nuclease system of any one of claims 33 to 38, wherein the engineered endonuclease is non-covalently bound to the engineered guide polynucleotide.
40. The engineered nuclease system of any one of claims 33 to 38, wherein the endonuclease is covalently linked to the engineered guide polynucleotide.
41. The engineered nuclease system of any one of claims 33 to 38, wherein the endonuclease is fused to the engineered guide polynucleotide.
42. The engineered nuclease system of any one of claims 33 to 41, wherein the engineered guide polynucleotide comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 111-113.
43. The engineered nuclease system of any one of claims 33 to 41, wherein the engineered guide polynucleotide comprises a sequence having 100% sequence identity to any one of SEQ ID NOs: 111-113.
44. The engineered nuclease system of any one of claims 33 to 43, wherein the engineered endonuclease is configured to bind to a PAM comprising any one of SEQ ID NOs: 117 and 2855-2862.
45. An engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the nuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within an albumin gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 67-86.
46. An engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the nuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a TRAC gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617.
47. The engineered nuclease system of claim 46, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 139-158, 925-927, 992-1011, 1184-1279, 1321-1361, 2486-2581, and 2618-2653.
48. An engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the nuclease and comprising a spacer sequence configured to hybridize with at least a portion of the target nucleic acid sequence within the B2M gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 159-184.
49. The engineered nuclease system of claim 48, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 185-210.
50. An engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the nuclease and comprising a spacer sequence configured to hybridize with at least a portion of the target nucleic acid sequence within the TRBC1 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity with any one of SEQ ID NOs: 211-251.
51. The engineered nuclease system of claim 50, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 252-292.
52. An engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the nuclease and comprising a spacer sequence configured to hybridize with at least a portion of the target nucleic acid sequence within the TRBC2 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 293-337.
53. The engineered nuclease system of claim 52, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 338-382.
54. An engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the nuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within an ANGPTL3 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 383-477, 1392-1489, 2120-2215, and 2312-2350.
55. The engineered nuclease system of claim 54, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 478-572, 1490-1587, 2216-2311, and 2351-2389.
56. An engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the nuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a PCSK9 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 573-587 and 1362-1376.
57. The engineered nuclease system of claim 56, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 588-602 and 1377-1391.
58. An engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the nuclease and comprising a spacer sequence configured to hybridize with at least a portion of the target nucleic acid sequence within the VCP gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 723-738 and 755-762.
59. The engineered nuclease system of claim 58, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 739-754 and 763-770.
60. An engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the nuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the AAVS1 locus or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 928-949 and 1012-1049.
61. The engineered nuclease system of claim 60, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 950-971 and 1050-1087.
62. An engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the nuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within a GPR146 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1588-1656.
63. The engineered nuclease system of claim 62, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1657-1725.
64. An engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the nuclease and comprising a spacer sequence configured to hybridize with at least a portion of a target nucleic acid sequence within the APOA1 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1726-1744, 1764-1774, 1866-1961, and 2058-2088.
65. The engineered nuclease system of claim 64, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1745-1763, 1775-1785, 1962-2057, and 2089-2119.
66. An engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the nuclease and comprising a spacer sequence configured to hybridize with at least a portion of a target nucleic acid sequence within the HAO1 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 611-633, 1789-1826, and 1827-1865.
67. A method for modifying a target nucleic acid sequence, the method comprising contacting the target nucleic acid sequence using an endonuclease according to any one of claims 1 to 32 or an engineered nuclease system according to any one of claims 33 to 66.
68. The method of claim 67, wherein modifying the target nucleic acid sequence comprises binding to, nicking, or cleaving the target nucleic acid sequence.
69. The method of any one of claims 67 to 68, wherein the target nucleic acid sequence comprises genomic DNA, viral DNA, viral RNA, or bacterial DNA.
70. The method of any one of claims 67 to 69, wherein the modification is in vitro.
71. The method of any one of claims 67 to 69, wherein the modification is in vivo.
72. The method of any one of claims 67 to 69, wherein the modification is ex vivo.
73. The method of any one of claims 67 to 72, wherein the gRNA is encoded by a sequence having any one of SEQ ID NOs: 251-260, 271-274, and 279-290.
74. The method of any one of claims 67 to 72, wherein the target nucleic acid sequence comprises a sequence having any one of SEQ ID NOs: 261-270, 275-278, and 291-302.
75. A method of modifying a target nucleic acid sequence in a mammalian cell, the method comprising contacting the mammalian cell with an endonuclease according to any one of claims 1 to 32 or an engineered nuclease system according to any one of claims 33 to 66.
76. The method of claim 75, further comprising selecting cells comprising the modification.
77. A method of modifying an albumin gene, the method comprising contacting the albumin gene with an engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the nuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the albumin gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 67-86.
78. A method for modifying a TRAC gene, the method comprising contacting the TRAC gene with an engineered nuclease system, the engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the nuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the TRAC gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 119-138, 922-924, 972-991, 1088-1183, 1280-1320, 2390-2485, and 2582-2617.
79. The method of claim 78, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 139-158, 925-927, 992-1011, 1184-1279, 1321-1361, 2486-2581, and 2618-2653.
80. A method for modifying a B2M gene, the method comprising contacting the B2M gene with an engineered nuclease system, the engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the nuclease and comprising a spacer sequence, wherein the spacer sequence is configured to hybridize with at least a portion of the target nucleic acid sequence within the B2M gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity with any one of SEQ ID NOs: 159-184.
81. The method of claim 80, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 185-210.
82. A method for modifying a TRBC1 gene, the method comprising contacting the TRBC1 gene with an engineered nuclease system, the engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the nuclease and comprising a spacer sequence, wherein the spacer sequence is configured to hybridize with at least a portion of the target nucleic acid sequence within the TRBC1 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity with any one of SEQ ID NOs: 211-251.
83. The method of claim 82, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 252-292.
84. A method for modifying a TRBC2 gene, the method comprising contacting the TRBC2 gene with an engineered nuclease system, the engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the nuclease and comprising a spacer sequence, wherein the spacer sequence is configured to hybridize with at least a portion of the target nucleic acid sequence within the TRBC2 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity with any one of SEQ ID NOs: 293-337.
85. The method of claim 84, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 338-382.
86. A method of modifying an ANGPTL3 gene, the method comprising contacting the ANGPTL3 gene with an engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the nuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the ANGPTL3 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 383-477, 1392-1489, 2120-2215, and 2312-2350.
87. The method of claim 86, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 478-572, 1490-1587, 2216-2311, and 2351-2389.
88. A method for modifying a PCSK9 gene, the method comprising contacting the PCSK9 gene with an engineered nuclease system, the engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the nuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the PCSK9 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 573-587 and 1362-1376.
89. The method of claim 88, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 588-602 and 1377-1391.
90. A method for modifying a VCP gene, the method comprising contacting the VCP gene with an engineered nuclease system, the engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the nuclease and comprising a spacer sequence configured to hybridize with at least a portion of a target nucleic acid sequence within the VCP gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 723-738 and 755-762.
91. The method of claim 90, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 739-754 and 763-770.
92. A method of modifying an AAVS1 locus, the method comprising contacting the AAVS1 locus with an engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the nuclease and comprising a spacer sequence configured to hybridize with at least a portion of a target nucleic acid sequence within the AAVS1 locus or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 928-949 and 1012-1049.
93. The method of claim 92, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 950-971 and 1050-1087.
94. A method for modifying a GPR146 gene, the method comprising contacting the GPR146 gene with an engineered nuclease system, the engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the nuclease and comprising a spacer sequence configured to hybridize to at least a portion of a target nucleic acid sequence within the GPR146 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1588-1656.
95. The method of claim 94, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1657-1725.
96. A method for modifying an APOA1 gene, the method comprising contacting the APOA1 gene with an engineered nuclease system, the engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the nuclease and comprising a spacer sequence configured to hybridize with at least a portion of a target nucleic acid sequence within the APOA1 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1726-1744, 1764-1774, 1866-1961, and 2058-2088.
97. The method of claim 96, wherein the target nucleic acid sequence comprises a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1745-1763, 1775-1785, 1962-2057, and 2089-2119.
98. A method for modifying a TRAC gene, the method comprising contacting the TRAC gene with an engineered nuclease system comprising: a) an engineered endonuclease comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-27 and 771-862; and b) an engineered guide polynucleotide configured to form a complex with the nuclease and comprising a spacer sequence configured to hybridize with at least a portion of a target nucleic acid sequence within the HAO1 gene or within an intron of an endogenous gene, the engineered guide polynucleotide comprising a sequence having at least 90% sequence identity to any one of SEQ ID NOs: 611-633, 1789-1826, and 1827-1865.
99. A cell comprising the endonuclease of any one of claims 1 to 32 or the engineered nuclease system of any one of claims 33 to 66.
100. The cell of claim 99, wherein the cell is a eukaryotic cell.
101. The cell of claim 99, wherein the cell is a mammalian cell.
102. The cell of claim 99, wherein the cell is an immortalized cell.
103. The cell of claim 99, wherein the cell is an insect cell.
104. The cell of claim 99, wherein the cell is a yeast cell.
105. The cell of claim 99, wherein the cell is a plant cell.
106. The cell of claim 99, wherein the cell is a fungal cell.
107. The cell of claim 99, wherein the cell is a prokaryotic cell.
108. The cell of claim 99, wherein the cell is A549, HEK-293, HEK-293T, BHK, CHO, HeLa, MRC5, Sf9, Cos-1, Cos-7, Vero, BSC 1, BSC 40, BMT 10, WI38, HeLa, Saos, C2C12, L cell, HT1080, HepG2, Huh7, K562, a primary cell, or a derivative thereof.
109. The cell of claim 99, wherein the cell is an engineered cell.
110. The cell of claim 99, wherein the cell is a stable cell.
